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tides, to DNA encoding precursors of the P-superfamily 
conopeptides and to the precursor peptides.




CROSS-REFERENCE TO RELATED 
APPLICATIONS
[0001] The present application is a continuation o f U.S. 
patent application Ser. No. 10/354,047 filed 30 Jan. 2003, 
which in turn is a divisional o f U.S. patent application Ser. 
No. 09/714,890 filed 17 Nov. 2000. U.S. Ser. No.09/714,890 
in turn is related to and claims priority under 35 U.S.C. 
§119(e) to U.S. provisional patent application Ser. No. 
60/165,933 filed on 17 Nov. 1999 and to U.S. provisional 
patent application Ser. No. 60/234,762 filed on 22 Sep. 2000. 
Each application is incorporated herein by reference.
[0002] This invention was made with Government support 
under Grant No. P01 GM48677 awarded by the National 
Institutes o f Health, Bethesda, Md. The United States Gov­
ernment has certain rights in the invention.
BACKGROUND OF THE INVENTION
[0003] The present invention is directed to P-superfamily 
conopeptides, to cDNA clones encoding precursors o f the 
P-superfamily conopeptides and to the precursor peptides.
[0004] The publications and other materials used herein to 
illuminate the background of the invention, and in particular, 
cases to provide additional details respecting the practice, 
are incorporated by reference, and for convenience are 
numerically referenced in the following text and respec­
tively grouped in the appended bibliography.
[0005] Conus is a genus of predatory marine gastropods 
(snails) which envenomate their prey. Venomous cone snails 
use a highly developed apparatus to deliver their cocktail o f 
toxic conotoxins into their prey. In fish-eating species such 
as Conus magus the cone detects the presence o f the fish 
using chemosensors in its siphon. When close enough 
extends its proboscis and impales the fish with a hollow 
harpoon-like tooth containing venom. This immobilizes the 
fish and enables the cone snail to wind it into its mouth 
viathe tooth held at the end o f its proboscis. For general 
information on Conus and their venom see the website 
address http://grimwade.biochem.unimelb.edu.au/cone/ref- 
erenc.html. Prey capture is accomplished through a sophis­
ticated arsenal o f peptides which taiget specific ion channel 
and receptor subtypes. Each Conus species venom appears 
to contain a unique set o f 50-200 peptides. The composition 
o f the venom differs greatly between species and between 
individual snails within each species, each optimally 
evolved to paralyse it’s prey. The active components o f the 
venom are small peptides toxins, typically 10-30 amino acid 
residues in length and are typically highly constrained 
peptides due to their high density o f disulphide bonds.
[0006] The venoms consist o f a large number o f different 
peptide components that when separated exhibit a range of 
biological activities: when injected into mice they elicit a 
range of physiological responses from shaking to depres­
sion. The paralytic components o f the venom that have been 
the focus o f recent investigation are the a ,  m- and (x-cono- 
toxins. All o f these conotoxins act by preventing neuronal 
communication, but each targets a different aspect o f the 
process to achieve this. The a-conotoxins target nicotinic 
ligand gated channels, the (x-conotoxins target the voltage- 
gated sodium channels and the m-conotoxins taiget the
voltage-gated calcium channels (Olivera et al., 1985; Oliv­
era et al., 1990). For example a linkage has been established 
between a -, aA -&  ^-conotoxins and the nicotinic ligand- 
gated ion channel; m-conotoxins and the voltage-gated cal­
cium channel; (x-conotoxins and the voltage-gated sodium 
channel; 8-conotoxins and the voltage-gated sodium chan­
nel; K-conotoxins and the voltage-gated potassium channel; 
conantokins and the ligand-gated glutamate (NMDA) chan­
nel.
[0007] However, the structure and function o f only a small 
minority o f these peptides have been determined to date. For 
peptides where function has been determined, three classes 
o f targets have been elucidated: voltage-gated ion channels; 
ligand-gated ion channels, and G-protein-linked receptors.
[0008] Conus peptides which target voltage-gated ion 
channels include those that delay the inactivation o f sodium 
channels, as well as blockers specific for sodium channels, 
calcium channels and potassium channels. Peptides that 
target ligand-gated ion channels include antagonists o f 
NMDA and serotonin receptors, as well as competitive and 
noncompetitive nicotinic receptor antagonists. Peptides 
which act on G-protein receptors include neurotensin and 
vasopressin receptor agonists. The unprecedented pharma­
ceutical selectivity o f conotoxins is at least in part defined by 
specific disulfide bond frameworks combined with hyper­
variable amino acids within disulfide loops (for a review see 
McIntosh et al., 1998).
[0009] There are drugs used in the treatment o f pain, 
which are known in the literature and to the skilled artisan. 
See, for example, Merck Manual, 16th Ed. (1992). However, 
there is a demand for more active analgesic agents with 
diminished side effects and toxicity and which are non- 
addictive. The ideal analgesic would reduce the awareness 
o f pain, produce analgesia over a wide range o f pain types, 
act satisfactorily whether given orally or parenterally, pro­
duce minimal or no side effects, be free from tendency to 
produce tolerance and drug dependence.
[0010] Due to the high potency and exquisite selectivity o f 
the conopeptides, several are in various stages o f clinical 
development for treatment of human disorders. For example, 
two Conus peptides are being developed for the treatment o f 
pain. The most advanced is m-conotoxin MVIIA 
(ziconotide), an N-type calcium channel blocker (see Head­
ing, C , 1999; U.S. Pat. No. 5,859,186). m-Conotoxin 
MVIIA, isolated from Conus magus, is approximately 1000 
times more potent than morphine, yet does not produce the 
tolerance or addictive properties o f opiates. m-Conotoxin 
MVIIA has completed Phase III (final stages) o f human 
clinical trials and has been approved as a therapeutic agent. 
m-Conotoxin MVIIA is introduced into human patients by 
means o f an implantable, programmable pump with a cath­
eter threaded into the intrathecal space. Preclinical testing 
for use in post-surgical pain is being carried out on another 
Conus peptide, contulakin-G, isolated from Conus geogra- 
phus (Craig et al. 1999). Contulakin-G is a 16 amino acid 
O-linked glycopeptide whose C-terminus resembles neuro­
tensin. It is an agonist o f neurotensin receptors, but appears 
significantly more potent than neurotensin in inhibiting pain 
in in vivo assays.
[0011] In view o f a laige number o f biologically active 
substances in Conus species it is desirable to further char­
acterize them and to identify peptides capable o f treating
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disorders involving voltage gated ion channels and/or recep­
tors, such as anti-convulsant agents. Surprisingly, and in 
accordance with this invention, Applicants have discovered 
novel conotoxins that can be useful for the treatment o f 
disorders involving voltage gated ion channels and/or recep­
tors and could address a long felt need for a safe and 
effective treatment.
SUMMARY OF THE INVENTION
[0012] In one aspect, the present invention is directed to 
P-superfamily conopeptides which have the generic 
sequence
[0013] Xaal-Xaa2-Cys-Xaa3-Xaa4-Xaa5-Xaa6-Cys- 
X aa7-X aa8-X aa9-X aal0-X aall-Cys-X aal2-X aal3-X aal4- 
Cys-Xaal 5-Xaal 6-Cys-Xaal 7-Xaal 8-Xaal 9-Xaa20- 
Xaa21-Cys-Xaa22-Xaa23-Xaa24-Xaa25-Xaa26-Xaa27- 
Xaa28 (SEQ ID NO: 1)
[0014] where X aal may be Ser, Ala, Asn, Leu, Thr, Gly, 
g-Thr (g is glycan; i.e., the Thr is glycosylated) or g-Ser; 
Xaa2 may be des-Xaa2, Ser, Thr, Gly, g-Thr or g-Ser; Xaa3 
may be Asn, Gin, Gly, Thr, Ser, g-Thr or g-Ser; Xaa4 may 
be des-Xaa4 or Gly; Xaa5 may be des-Xaa5, Asn or Asp; 
Xaa6 may be Ser, Thr, Pro, Hyp (hydroxy-Pro), g-Thr or 
g-Ser; Xaa7 may be Asn, Gin, Thr, Ser, g-Thr or g-Ser; X aa8 
may be Glu, Ser, Asn, Met, Thr, Gla (y-carboxy-Glu), Nle 
(norleucine), Asp, Gin, g-Thr or g-Ser; Xaa9 may be His, 
Ser, Asp, Thr, g-Thr or g-Ser; XaalO may be Ser, Ala, Pro, 
Hyp, Thr, g-Thr or g-Ser; X aal 1 may be Asp, Glu Gla or any 
synthetic acidic amino acid; X aal2  may be des-Xaal2, Glu, 
Asp, Pro, Hyp, Gla, Ala, Tyr, meta-Tyr, ortho-Tyr, nor-Tyr, 
mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, 
nitro-Tyr or any synthetic acidic amino acid; X aal3  may be 
Ser, Asn, Gly, Thr, Hyp, g-Thr, g-Ser or any synthetic 
hydroxy containing amino acid; Xaa 14 may be His, Thr, 
Phe, Asn, lie, Ser, Gin, g-Ser, g-Thr, any synthetic hydroxy 
containing amino acid, Trp (D or L), neo-Trp, halo-Trp (D 
or L) or any synthetic aromatic amino acid; Xaa 15 may be 
lie, Ser, Asp, Glu, Gla, any synthetic amino acid, Thr, g-Ser, 
g-Thr, any synthetic hydroxy containing amino acid, Tyr, 
meta-Tyr, ortho-Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, 
O-sulpho-Tyr, O-phospho-Tyr or nitro-Tyr; X aal 6 maybe 
des-X aal6, Thr, Ser, g-Thr, g-Ser or any synthetic hydroxy 
containing amino acid; X aal7  may be des-Xaal7, Asp, Glu, 
Gla or any synthetic acidic amino acid; Xaa 18 may be Thr, 
Leu, lie, Val, Ser, g-Thr, g-Ser or any synthetic hydroxy 
containing amino acid; Xaa 19 may be Phe, His, Gly, Glu, 
Asp, Gla, any synthetic acidic amino acid, Ser, Thr, g-Ser, 
g-Thr, any synthetic hydroxy containing amino acid, Trp (D 
or L), neo-Trp, halo-Trp (D or L) or any synthetic aromatic 
amino acid; Xaa20 maybe Ser, Thr, Ala, Asp, Asn, Gin, 
g-Ser, g-Thr, His, Arg, ornithine, homo-Lys, homoaiginine, 
nor-Lys, N-methyl-Lys, N,N'-dimethyl-Lys, N,N',N"-trim- 
ethyl-Lys or any synthetic basic amino acid; Xaa21 may be 
Gly, Gin, Asn, His, Arg, ornithine, homo-Lys, homoaiginine, 
nor-Lys, N-methyl-Lys, N,N'-dimethyl-Lys, N,N',N"-trim- 
ethyl-Lys or any synthetic basic amino acid; Xaa22 may be 
Gly, Glu, Asp, Gla, any synthetic acidic amino acid, lie, His, 
Arg, ornithine, homo-Lys, homoarginine, nor-Lys, N-me- 
thyl-Lys, N,N'-dimethyl-Lys, N,N',N"-trimethyl-Lys or any 
synthetic basic amino acid; Xaa23 may be des-Xaa23, lie, 
Ala, Ser, Pro, Hyp, Phe, Thr, g-Thr, g-Ser or any synthetic 
hydroxy containing amino acid; Xaa24 may be des-Xaa24, 
He, Val, Thr, Asp, Phe, Ser, g-Thr, g-Ser or any synthetic
hydroxy containing amino acid; Xaa25 may be des-Xaa25, 
Met, Nle, His, Arg, ornithine, homo-Lys, homoarginine, 
nor-Lys, N-methyl-Lys, N,N'-dimethyl-Lys, N,N',N"-trim- 
ethyl-Lys or any synthetic basic amino acid; Xaa26 may be 
des-Xaa26, His, Arg, ornithine, homo-Lys, homoarginine, 
nor-Lys, N-methyl-Lys, N,N'-dimethyl-Lys, N,N',N"-trim- 
ethyl-Lys or any synthetic basic amino acid; Xaa27 may be 
des-Xaa27, Leu, Asn, Gin, Glu, Asp, Gla or any synthetic 
amino acid; and Xaa28 may be des-Xaa28, He, His, Arg, 
ornithine, homo-Lys, homoarginine, nor-Lys, N-methyl-Lys, 
N,N'-dimethyl-Lys, N,N',N"-trimethyl-Lys or any synthetic 
basic amino acid. The C-terminus may contain a free car­
boxyl group or an amide group.
[0015] More specifically, the present invention is directed 
to P-superfamily conopeptides, having the following amino 
acid sequences:
(SEQ ID NO: 2) 
Ser-Cys-Asn-Asn-Ser-Cys-Asn-Xaal-His-Ser-Asp-Cys- 
X aal-Ser-H is-C ys-Ile-Cys-Thr-Phe-Ser-G ly-C ys-Lys- 
I l e - I le -L e u - I le ;
(SEQ ID NO: 3) 
Ser-Cys-Asn-Asn-Ser-Cys-Asn-Xaal-His-Ser-Asp-Cys- 
X aal-Ser-His-Cys-Ile-Cys-Thr-Phe-Arg-Gly-Cys-G ly- 
Ala-Val-Asn;












(SEQ ID NO: 7) 
Ser-Cys-Asn-Asn-Ser-Cys-Gln-Ser-His-Ser-Asp-Cys- 
A la-Ser-His-Cys-Ile-Cys-Thr-Phe-Arg-Gly-Cys-G ly- 
Ala-Val-Asn;




(SEQ ID NO: 9) 
Leu-Thr-Cys-Asn-Asp-Xaa3-Cys-Gln-Met-His-Ser-Asp- 
Cys-G ly-Ile-Cys-Xaal-Cys-V al-Xaal-A sn-Lys-Cys-Ile- 
Phe-Phe-Met;
(SEQ ID NO: 10) 
Gly-Cys-Asn-Asn-Ser-Cys-Gln-Xaal-His-Ser-Asp-Cys- 
X aal-Ser-His-Cys-Ile-Cys-Thr-Phe-Arg-Gly-Cys-G ly- 
Ala-Val-Asn; 
and
(SEQ ID NO: 11) 
Gly-Cys-Asn-Asn-Ser-Cys-Gln-Xaal-His-Ser-Asp-Cys- 
X aal-Ser-H is-Cys-Ile-Cys-Thr-Ser-A rg-G ly-Cys-G ly- 
Ala-Val-Asn,
[0016] wherein X aal is Glu or y-carboxy-Glu; Xaa3 is Pro 
orhydroxy-Pro; Xaa5 is Tyr, 125I-Tyr, mono-iodo-Tyr, di- 
iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr; and the C-termi- 
nus contains an amide group or a carboxyl group.
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[0017] More specifically, the present invention is directed 
to the following P-Superfamily conopeptides:
[0018] Af9.1: SEQ ID NO:2, wherein X aal is Glu;
[0019] Af9.2: SEQ ID NO:3, wherein X aal is Glu;
[0020] Ca9.1: SEQ ID NO:4, wherein X aal is Glu and 
Xaa3 is Pro;
[0021] Ca9.2: SEQ ID NO:5, wherein X aal is Glu and 
Xaa3 is Pro;
[0022] Cn9.1: SEQ ID N O:6, wherein X aal is Glu and 
Xaa5 is Tyr;
[0023] Gm9.1: SEQ ID NO:7;
[0024] Im9 1: SEQ ID NO:8, wherein X aal is Glu, Xaa3 
is Pro and Xaa5 is Tyr;
[0025] Pn9.1: SEQ ID NO:9, wherein X aal is Glu and 
Xaa3 is Pro;
[0026] tx9a (Tx9.1): SEQ ID N 0:10, w hereinX aal is Glu 
or Gla; and
[0027] U030: SEQ ID NO: I 1, wherein X aal is Glu or 
Gla.
[0028] The C-terminus o f Af9.1, Ca9.1, Ca9.2, Cn9.1, 
Im9.1 and Pn9.1 preferably contains free carboxy group. 
The C-terminus o f Af9.2, Gm9. 1, tx9a and U030 preferably 
contains an amide group.
[0029] The present invention is also directed to derivatives 
or pharmaceutically acceptable salts o f the P-superfamily 
genus or conopeptides. Examples o f derivatives include 
peptides in which the Arg residues may be substituted by 
Lys, ornithine, homoaigine, nor-Lys, N-methyl-Lys, N,N- 
dimethyl-Lys, N,N,N-trimethyl-Lys or any synthetic basic 
amino acid; the Lys residues may be substituted by Arg, 
ornithine, homoargine, nor-Lys, or any synthetic basic 
amino acid; the Tyr residues may be substituted with meta- 
Tyr, ortho-Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sul- 
pho-Tyr, O-phospho-Tyr, nitro-Tyr or any synthetic hydroxy 
containing amino acid; the Ser residues may be substituted 
with Thr or any synthetic hydroxylated amino acid; the Thr 
residues may be substituted with Ser or any synthetic 
hydroxylated amino acid; the Phe residues may be substi­
tuted with any synthetic aromatic amino acid; the Trp 
residues may be substituted with Trp (D), neo-Trp, halo-Trp 
(D or L) or any aromatic synthetic amino acid; and the Asn, 
Ser, Thr or Hyp residues may be glycosylated. The halogen 
may be iodo, chloro, fluoro or bromo; preferably iodo for 
halogen substituted-Tyr and bromo for halogen-substituted 
Trp. The Tyr residues may also be substituted with the 
3-hydroxyl or 2-hydroxyl isomers (meta-Tyr or ortho-Tyr, 
respectively) and corresponding O-sulpho- and O-phospho- 
derivatives. The acidic amino acid residues may be substi­
tuted with any synthetic acidic amino acid, e.g., tetrazolyl 
derivatives of Gly and Ala. The aliphatic amino acids may 
be substituted by synthetic derivatives bearing non-natural 
aliphatic branched or linear side chains CnH2n+2 up to and 
including n=8 . The Leu residues may be substituted with 
Leu (D). The Glu residues may be substituted with Gla. The 
Gla residues may be substituted with Glu. The Met residues 
may be substituted with norleucine (Nle). The Cys residues 
may be in D or L configuration and may optionally be 
substituted with homocysteine (D or L).
[0030] Examples o f synthetic aromatic amino acid 
include, but are not limited to, nitro-Phe, 4-substituted-Phe 
wherein the substituent is C ^ ^  alkyl, carboxyl, 
hyrdroxymethyl, sulphomethyl, halo, phenyl, — CHO, 
— CN, — S 0 3H and -NHAc. Examples o f synthetic hydroxy 
containing amino acid, include, but are not limited to, such 
as 4-hydroxymethyl-Phe, 4-hydroxyphenyl-Gly, 2,6-dim- 
ethyl-Tyr and 5-amino-Tyr. Examples o f synthetic basic 
amino acids include, but are not limited to, N-l-(2-pyrazoli- 
nyl)-Aig, 2-(4-piperidinyl)-Gly, 2-(4-piperidinyl)-Ala, 2-[3-
(2S)pyrrolidinyl)-Gly and 2-[3-(2S)pyrrolidinyl)-Ala. These 
and other synthetic basic amino acids, synthetic hydroxy 
containing amino acids or synthetic aromatic amino acids 
are described in Building Block Index, Version 3.0 (1999 
Catalog, pages 4-47 for hydroxy containing amino acids and 
aromatic amino acids and pages 66-87 for basic amino acids; 
see also http://www.amino-acids.com), incorporated herein 
by reference, by and available from RSP Amino Acid 
Analogues, Inc., Worcester, Mass. The residues containing 
protecting groups are deprotected using conventional tech­
niques. Examples o f synthetic acid amino acids include 
those derivatives bearing acidic functionality, including car­
boxyl, phosphate, sulfonate and synthetic tetrazolyl deriva­
tives such as described by Omstein et al. (1993) and in U.S. 
Pat. No. 5,331,001, each incorporated herein by reference.
[0031] Optionally, in the conotoxin peptides o f the present 
invention, the Asn residues may be modified to contain an 
N-glycan and the Ser, Thr and Hyp residues may be modi­
fied to contain an O-glycan (e.g., g-N, g-S, g-T and g-Hyp). 
In accordance with the present invention, a glycan shall 
mean any N-, S- or O-linked mono-, di-, tri-, poly- or 
oligosaccharide that can be attached to any hydroxy, amino 
or thiol group o f natural or modified amino acids by syn­
thetic or enzymatic methodologies known in the art. The 
monosaccharides making up the glycan can include D-al- 
lose, D-altrose, D-glucose, D-mannose, D-gulose, D-idose, 
D-galactose, D-talose, D-galactosamine, D-glucosamine, 
D-N-acetyl-glucosamine (GlcNAc), D-N-acetyl-galac- 
tosamine (GalNAc), D-fucose or D-arabinose. These sac­
charides may be structurally modified, e.g., with one or more 
O-sulfate, O-phosphate, O-acetyl or acidic groups, such as 
sialic acid, including combinations thereof. The gylcan may 
also include similar polyhydroxy groups, such as D-peni- 
cillamine 2,5 and halogenated derivatives thereof or 
polypropylene glycol derivatives. The glycosidic linkage is 
beta and 1-4 or 1-3, preferably 1-3. The linkage between the 
glycan and the amino acid may be alpha or beta, preferably 
alpha and is 1-.
[0032] Core O-glycans have been described by Van de 
Steen et al. (1998), incorporated herein by reference. Mucin 
type O-linked oligosaccharides are attached to Ser or Thr (or 
other hydroxylated residues o f the present peptides) by a 
GalNAc residue. The monosaccharide building blocks and 
the linkage attached to this first GalNAc residue define the 
“core glycans,” o f which eight have been identified. The 
type o f glycosidic linkage (orientation and connectivities) 
are defined for each core glycan. Suitable glycans and 
glycan analogs are described further in U.S. Ser. No. 09/420, 
797 filed 19 Oct. 1999 and in PCT Application No. PCT/ 
US99/24380 filed 19 Oct. 1999 (PCT Published Application 
No. WO 00/23092), each incorporated herein by reference. 
A  preferred glycan is Gal((31—»3)G alN A c(al—»).
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[0033] Optionally, in the conotoxin peptides described 
above, pairs o f Cys residues maybe replaced pairwise with 
isoteric lactam or ester-thioether replacements, such as Ser/ 
(Glu or Asp), Lys/(Glu or Asp), Cys/(Glu or Asp) or Cys/Ala 
combinations. Sequential coupling by known methods (Bar- 
naye ta l., 2000; Hraby et al., 1994; Bitan etal., 1997) allows 
replacement o f native Cys bridges with lactam bridges. 
Thioether analogs may be readily synthesized using halo- 
Ala residues commercially available from RSP Amino Acid 
Analogues.
[0034] The present invention is further directed to deriva­
tives o f the above peptides and peptide derivatives which are 
cylic permutations in which the cyclic permutants retain the 
native bridging pattern of native toxin. See Craik et al. 
(2001).
[0035] In a second aspect, the present invention is further 
directed to DNA clones encoding the precursors o f the 
biologically-active mature peptides and to the precursor 
peptides.
[0036] In a third aspect, the present invention is further 
directed to the use o f a member o f the P-superfamily o f 
conopeptides for screening drugs for anti-convulsant activ­
ity. A  member o f the P-superfamily may also be used to 
isolate or assay for its receptor.
[0037] In a fourth aspect, the present invention is further 
directed to a method of identifying compounds that mimic 
the therapeutic activity o f P-Superfamily conopeptides, 
comprising the steps of: (a) conducting a biological assay on 
a test compound to determine the therapeutic activity; and 
(b) comparing the results obtained from the biological assay 
o f the test compound to the results obtained from the 
biological assay of a P-Superfamily conopeptides. The 
P-Superfamily conopeptide is labeled with any conventional 
label, preferably a 125I radioisotope on an available Tyr. 
Thus, the invention is also directed to radioiodinated P-Su- 
perfamily conopeptides.
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS
[0038] The present invention is directed to P-superfamily 
conopeptides which have the generic sequence shown above 
or specific P-superfamily conopeptides disclosed herein or 
derivatives thereof.
[0039] The present invention is further directed to cDNA 
clones encoding the precursor o f the biologically-active 
mature peptides and to the precursor peptides. The DNA and 
precursor proteint sequences are set forth in Table 1
[0040] The invention is further directed to the use o f these 
peptides for screening drugs for anticonvulsant activity and 
to isolate and assay receptors.
[0041] The isolation and characterization of the conopep­
tide tx9a (also called spasmodic peptide or tx9.1) is 
described herein, as well as the isolation o f DNA coding for 
conopeptide tx9a and the isolation of DNA directed to 
additional members o f the P-Superfamily. The correspond­
ing amino acid sequences o f the precursor peptides for 
members o f the P-Superfamily, and the mature peptide 
sequences o f are also disclosed. As disclosed herein, tx9a 
elicits a spastic or spasmotic response when injected into 
mice. The spastic or spasmotic response is the same as seen
in two well known mutant mouse strains, the spastic mouse 
and the spasmodic mouse. Since tx9a induces spasticity, it is 
thus known to have high affinity and specificity for a 
particular receptor and can be used to taiget this receptor and 
in assays for this receptor. tx9a and other members o f the 
P-Superfamily are also useful for screening drugs for anti­
convulsant activity.
[0042] The conopeptides o f the present invention are 
identified by isolation from Conus venom. Alternatively, the 
conopeptides o f the present invention are identified using 
recombinant DNA techniques by screening cDNA libraries 
o f various Conus species using conventional techniques 
such as the use o f reverse-transcriptase polymerase chain 
reaction (RT-PCR) or the use of degenerate probes. Primers 
for RT-PCR are based on conserved sequences in the signal 
sequence and 3' untranslated region o f the P-superfamily 
conopeptide genes. Clones which hybridize to these probes 
are analyzed to identify those which meet minimal size 
requirements, i.e., clones having approximately 300 nucle­
otides (for a propeptide), as determined using PCR primers 
which flank the cDNA cloning sites for the specific cDNA 
library being examined. These minimal-sized clones are 
then sequenced. The sequences are then examined for the 
presence o f a peptide having the characteristics noted above 
for conopeptides. The biological activity o f the peptides 
identified by this method is tested as described herein, in 
U.S. Pat. No.5,635,347 or conventionally in the art.
[0043] These peptides are sufficiently small to be chemi­
cally synthesized. General chemical syntheses for preparing 
the foregoing conopeptides are described hereinafter, along 
with specific chemical synthesis o f conopeptides and indi­
cations of biological activities o f these synthetic products. 
Various ones o f these conopeptides can also be obtained by 
isolation and purification from specific Conus species using 
the techniques described in U.S. Pat. No. 4,447,356 (Olivera 
et a l,  1984), U.S. Pat. No. 5,514,774 (Olivera et a l,  1996) 
and U.S. Pat. No. 5,591,821 (Olivera et a l,  1997), the 
disclosures o f which are incorporated herein by reference.
[0044] Although the conopeptides o f the present invention 
can be obtained by purification from cone snails, because the 
amounts o f conopeptides obtainable from individual snails 
are very small, the desired substantially pure conopeptides 
are best practically obtained in commercially valuable 
amounts by chemical synthesis using solid-phase strategy. 
For example, the yield from a single cone snail may be about 
10 micrograms or less o f conopeptide. By “substantially 
pure” is meant that the peptide is present in the substantial 
absence o f other biological molecules o f the same type; it is 
preferably present in an amount o f at least about 85% purity 
and preferably at least about 95% purify. Chemical synthesis 
o f biologically active conopeptides depends o f course upon 
correct determination o f the amino acid sequence. Thus, the 
conopeptides of the present invention may be isolated, 
synthesized and/or substantially pure.
[0045] The conopeptides can also be produced by recom­
binant DNA techniques well known in the art. Such tech­
niques are described by Sambrook et al. (1989). The pep­
tides produced in this manner are isolated, reduced if  
necessary, and oxidized to form the correct disulfide bonds, 
if  present in the final molecule.
[0046] One method o f forming disulfide bonds in the 
conopeptides o f the present invention is the air oxidation o f
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the linear peptides for prolonged periods under cold room 
temperatures or at room temperature. This procedure results 
in the creation of a substantial amount o f the bioactive, 
disulfide-linked peptides. The oxidized peptides are frac­
tionated using reverse-phase high performance liquid chro­
matography (HPLC) or the like, to separate peptides having 
different linked configurations. Thereafter, either by com­
paring these fractions with the elution o f the native material 
or by using a simple assay, the particular fraction having the 
correct linkage for maximum biological potency is easily 
determined. It is also found that the linear peptide, or the 
oxidized product having more than one fraction, can some­
times be used for in vivo administration because the cross­
linking and/or rearrangement which occurs in vivo has been 
found to create the biologically potent conopeptide mol­
ecule. However, because of the dilution resulting from the 
presence o f other fractions o f less biopotency, a somewhat 
higher dosage may be required.
[0047] The peptides are synthesized by a suitable method, 
such as by exclusively solid-phase techniques, by partial 
solid-phase techniques, by fragment condensation or by 
classical solution couplings.
[0048] In conventional solution phase peptide synthesis, 
the peptide chain can be prepared by a series o f coupling 
reactions in which constituent amino acids are added to the 
growing peptide chain in the desired sequence. Use of 
various coupling reagents, e.g., dicyclohexylcarbodiimide or 
diisopropyl- carbonyldimidazole, various active esters, e.g., 
esters o f N-hydroxyphthalimide or N-hydroxy-succinimide, 
and the various cleavage reagents, to carry out reaction in 
solution, with subsequent isolation and purification o f inter­
mediates, is well known classical peptide methodology. 
Classical solution synthesis is described in detail in the 
treatise, “Methoden der Oiganischen Chemie (Houben- 
Weyl): Synthese von Peptiden,” (1974). Techniques of 
exclusively solid-phase synthesis are set forth in the text­
book, “Solid-Phase Peptide Synthesis,” (Stewart and Young, 
1969), and are exemplified by the disclosure o f U.S. Pat. No. 
4,105,603 (Vale et al., 1978). The fragment condensation 
method o f synthesis is exemplified in U.S. Pat. No. 3,972, 
859 (1976). Other available syntheses are exemplified by 
U.S. Pat. No. 3,842,067 (1974) and U.S. Pat. No. 3,862,925 
(1975). The synthesis o f peptides containing g-carboxy- 
glutamic acid residues is exemplified by Rivier et al. (1987), 
Nishiuchi et al. (1993) and Zhou et al. (1996). Synthesis o f 
conopeptides have been described in U.S. Pat. No. 4,447, 
356 (Olivera et a l ,  1984), U.S. Pat. No. 5,514,774 (Olivera 
et a l,  1996) and U.S. Pat. No. 5,591,821 (Olivera et a l,  
1997).
[0049] Common to such chemical syntheses is the protec­
tion o f the labile side chain groups o f the various amino acid 
moieties with suitable protecting groups which will prevent 
a chemical reaction from occurring at that site until the 
group is ultimately removed. Usually also common is the 
protection o f an a-am ino group on an amino acid or a 
fragment while that entity reacts at the carboxyl group, 
followed by the selective removal o f the a-am ino protecting 
group to allow subsequent reaction to take place at that 
location. Accordingly, it is common that, as a step in such a 
synthesis, an intermediate compound is produced which 
includes each of the amino acid residues located in its 
desired sequence in the peptide chain with appropriate
side-chain protecting groups linked to various ones o f the 
residues having labile side chains.
[0050] As far as the selection o f a side chain amino 
protecting group is concerned, generally one is chosen 
which is not removed during deprotection of the a-amino 
groups during the synthesis. However, for some amino 
acids, e.g., His, protection is not generally necessary. In 
selecting a particular side chain protecting group to be used 
in the synthesis o f the peptides, the following general rules 
are followed: (a) the protecting group preferably retains its 
protecting properties and is not split off under coupling 
conditions, (b) the protecting group should be stable under 
the reaction conditions selected for removing the a-amino 
protecting group at each step o f the synthesis, and (c) the 
side chain protecting group must be removable, upon the 
completion o f the synthesis containing the desired amino 
acid sequence, under reaction conditions that will not unde­
sirably alter the peptide chain.
[0051] It should be possible to prepare many, or even all, 
o f these peptides using recombinant DNA technology. How­
ever, when peptides are not so prepared, they are preferably 
prepared using the Merrifield solid-phase synthesis, 
although other equivalent chemical syntheses known in the 
art can also be used as previously mentioned. Solid-phase 
synthesis is commenced from the C-terminus of the peptide 
by coupling a protected a-am ino acid to a suitable resin. 
Such a starting material can be prepared by attaching an 
a-amino-protected amino acid by an ester linkage to a 
chloromethylated resin or a hydroxymethyl resin, or by an 
amide bond to a benzhydrylamine (BHA) resin or param- 
ethylbenzhydrylamine (MBHA) resin. Preparation o f the 
hydroxymethyl resin is described by Bodansky et al. (1966). 
Chloromethylated resins are commercially available from 
Bio Rad Laboratories (Richmond, Calif.) and from Lab. 
Systems, Inc. The preparation of such a resin is described by 
Stewart and Young (1969). BHA and MBHA resin supports 
are commercially available, and are generally used when the 
desired polypeptide being synthesized has an unsubstituted 
amide at the C-terminus. Thus, solid resin supports may be 
any o f those known in the art, such as one having the 
formulae — O— CH2-resin support, — NH BHA resin sup­
port, or — NH-M BHAresin support. When the unsubstituted 
amide is desired, use o f a BHA or MBHA resin is preferred, 
because cleavage directly gives the amide. In case the 
N-methyl amide is desired, it can be generated from an 
N-methyl BHA resin. Should other substituted amides be 
desired, the teaching o f U.S. Pat. No.4,569,967 (Kornreich 
et a l,  1986) can be used, or should still other groups than the 
free acid be desired at the C-terminus, it may be preferable 
to synthesize the peptide using classical methods as set forth 
in the Houben-Weyl text (1974).
[0052] The C-terminal amino acid, protected by Boc or 
Fmoc and by a side-chain protecting group, if  appropriate, 
can be first coupled to a chloromethylated resin according to 
the procedure set forth in Horiki et al. (1978), using KF in 
DMF at about 60° C. for 24 hours with stirring, when a 
peptide having free acid at the C-terminus is to be synthe­
sized. Following the coupling of the tert-Boc-protected 
amino acid to the resin support, the a-am ino protecting 
group is removed, as by using trifiuoroacetic acid (TFA) in 
methylene chloride or TFA alone. The deprotection is car­
ried out at a temperature between about 0° C. and room 
temperature. Other standard cleaving reagents, such as HC1
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in dioxane, and conditions for removal o f specific a-am ino 
protecting groups may be used as described in Schroder and 
Lubke (1965).
[0053] After removal o f the a-amino-protecting group, the 
remaining a-am ino- and side chain-protected amino acids 
are coupled step-wise in the desired order to obtain the 
intermediate compound defined hereinbefore, or as an alter­
native to adding each amino acid separately in the synthesis, 
some o f them may be coupled to one another prior to 
addition to the solid phase reactor. Selection of an appro­
priate coupling reagent is within the skill o f the art. Particu­
larly suitable as a coupling reagent is N,N'-dicyclohexylcar- 
bodiimide (DCC, DIC, HBTU, HATU, TBTU in the 
presence o f HoBt or Ho At).
[0054] The activating reagents used in the solid phase 
synthesis o f the peptides are well known in the peptide art. 
Examples o f suitable activating reagents are carbodiimides, 
such as N,N'-diisopropylcarbodiimide and N-ethyl-N'-(3- 
dimethylaminopropyl)carbodiimide. Other activating 
reagents and their use in peptide coupling are described by 
Schroder and Lubke (1965) and Kapoor (1970).
[0055] Each protected amino acid or amino acid sequence 
is introduced into the solid-phase reactor in about a twofold 
or more excess, and the coupling may be carried out in a 
medium o f dimethylformamide (DMF):CH2C12 (1:1) or in 
DMF or CH2C12 alone. In cases where intermediate coupling 
occurs, the coupling procedure is repeated before removal o f 
the a-am ino protecting group prior to the coupling o f the 
next amino acid. The success o f the coupling reaction at each 
stage of the synthesis, if  performed manually, is preferably 
monitored by the ninhydrin reaction, as described by Kaiser 
et al. (1970). Coupling reactions can be performed auto­
matically, as on a Beckman 990 automatic synthesizer, using 
a program such as that reported in Rivier et al. (1978).
[0056] After the desired amino acid sequence has been 
completed, the intermediate peptide can be removed from 
the resin support by treatment with a reagent, such as liquid 
hydrogen fluoride or TFA (ifusing Fmoc chemistry), which 
not only cleaves the peptide from the resin but also cleaves 
all remaining side chain protecting groups and also the 
a-am ino protecting group at the N-terminus if  it was not 
previously removed to obtain the peptide in the form of the 
free acid. I f  Met is present in the sequence, the Boc 
protecting group is preferably first removed using trifluoro- 
acetic acid (TFA)/ethanedithiol prior to cleaving the peptide 
from the resin with HF to eliminate potential S-alkylation. 
W hen using hydrogen fluoride or TFA for cleaving, one or 
more scavengers such as anisole, cresol, dimethyl sulfide 
and methylethyl sulfide are included in the reaction vessel.
[0057] Cyclization of the linear peptide is preferably 
affected, as opposed to cyclizing the peptide while a part o f 
the peptido-resin, to create bonds between Cys residues. To 
effect such a disulfide cyclizing linkage, fully protected 
peptide can be cleaved from a hydroxymethylated resin or a 
chloromethylated resin support by ammonolysis, as is well 
known in the art, to yield the fully protected amide inter­
mediate, which is thereafter suitably cyclized and depro­
tected. Alternatively, deprotection, as well as cleavage o f the 
peptide from the above resins or a benzhydrylamine (BHA) 
resin or a methylbenzhydrylamine (MBHA), can take place 
at 0° C. with hydrofluoric acid (HF) or TFA, followed by 
oxidation as described above. A  suitable method for cycliza­
tion is the method described by Cartier et al. (1996).
[0058] Muteins, analogs or active fragments, o f the fore­
going t-conotoxin peptides are also contemplated here. See, 
e.g., Hammerland et al (1992). Derivative muteins, analogs 
or active fragments o f the conotoxin peptides may be 
synthesized according to known techniques, including con­
servative amino acid substitutions, such as outlined in U.S. 
Pat. No. 5,545,723 (see particularly col. 2, line 50 to col. 3, 
line 8); U.S. Pat. No. 5,534,615 (see particularly col. 19, line 
45 to col. 33); and U.S. Pat. No. 5,364,769 (see particularly 
col. 4, line 55 to col. 7, line 26), each incorporated herein by 
reference.
[0059] Pharmaceutical compositions containing a com­
pound of the present invention as the active ingredient can 
be prepared according to conventional pharmaceutical com­
pounding techniques. See, for example, R em ington’s Phar­
m aceutical Sciences, 18th Ed. (1990, Mack Publishing C o , 
Easton, Pa.). Typically, an antagonistic amount o f active 
ingredient will be admixed with a pharmaceutically accept­
able carrier. The carrier may take a wide variety o f forms 
depending on the form o f preparation desired for adminis­
tration, e.g., intravenous, oral, parenteral or intrathecally. 
For examples o f delivery methods see U.S. Pat. No. 5,844, 
077, incorporated herein by reference.
[0060] “Pharmaceutical composition” means physically 
discrete coherent portions suitable for medical administra­
tion. “Pharmaceutical composition in dosage unit form” 
means physically discrete coherent units suitable for medical 
administration, each containing a daily dose or a multiple 
(up to four times) or a sub-multiple (down to a fortieth) o f 
a daily dose of the active compound in association with a 
carrier and/or enclosed within an envelope. Whether the 
composition contains a daily dose, or for example, a half, a 
third or a quarter o f a daily dose, will depend on whether the 
pharmaceutical composition is to be administered once or, 
for example, twice, three times or four times a day, respec­
tively.
[0061] The term “salt”, as used herein, denotes acidic 
and/or basic salts, formed with inoiganic or organic acids 
and/or bases, preferably basic salts. While pharmaceutically 
acceptable salts are preferred, particularly when employing 
the compounds o f the invention as medicaments, other salts 
find utility, for example, in processing these compounds, or 
where non-medicament-type uses are contemplated. Salts o f 
these compounds may be prepared by art-recognized tech­
niques.
[0062] Examples o f such pharmaceutically acceptable 
salts include, but are not limited to, inorganic and organic 
addition salts, such as hydrochloride, sulphates, nitrates or 
phosphates and acetates, trifluoroacetates, propionates, suc­
cinates, benzoates, citrates, tartrates, fumarates, maleates, 
methane-sulfonates, isothionates, theophylline acetates, sali­
cylates, respectively, or the like. Lower alkyl quaternary 
ammonium salts and the like are suitable, as well.
[0063] As used herein, the term “pharmaceutically accept­
able” carrier means a non-toxic, inert solid, semi-solid liquid 
filler, diluent, encapsulating material, formulation auxiliary 
o f any type, or simply a sterile aqueous medium, such as 
saline. Some examples o f the materials that can serve as 
pharmaceutically acceptable carriers are sugars, such as 
lactose, glucose and sucrose, starches such as com  starch 
and potato starch, cellulose and its derivatives such as 
sodium carboxymethyl cellulose, ethyl cellulose and cellu­
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lose acetate; powdered tragacanth; malt, gelatin, talc; excipi­
ents such as cocoa butter and suppository waxes; oils such 
as peanut oil, cottonseed oil, safllower oil, sesame oil, olive 
oil, com oil and soybean oil; glycols, such as propylene 
glycol, polyols such as glycerin, sorbitol, mannitol and 
polyethylene glycol; esters such as ethyl oleate and ethyl 
laurate, agar; buffering agents such as magnesium hydroxide 
and aluminum hydroxide; alginic acid; pyrogen-free water; 
isotonic saline, Ringer’s solution; ethyl alcohol and phos­
phate buffer solutions, as well as other non-toxic compatible 
substances used in pharmaceutical formulations.
[0064] Wetting agents, emulsifiers and lubricants such as 
sodium lauryl sulfate and magnesium stearate, as well as 
coloring agents, releasing agents, coating agents, sweeten­
ing, flavoring and perfuming agents, preservatives and anti­
oxidants can also be present in the composition, according 
to the judgment o f the formulator. Examples o f pharmaceu­
tically acceptable antioxidants include, but are not limited 
to, water soluble antioxidants such as ascorbic acid, cysteine 
hydrochloride, sodium bisulfite, sodium metabisulfite, 
sodium sulfite, and the like; oil soluble antioxidants, such as 
ascorbyl palmitate, butylated hydroxyanisole (BHA), buty- 
lated hydroxytoluene (BHT), lecithin, propyl gallate, aloha- 
tocopherol and the like; and the metal chelating agents such 
as citric acid, ethylenediamine tetraacetic acid (EDTA), 
sorbitol, tartaric acid, phosphoric acid and the like.
[0065] For oral administration, the compounds can be 
formulated into solid or liquid preparations such as capsules, 
pills, tablets, lozenges, melts, powders, suspensions or emul­
sions. In preparing the compositions in oral dosage form, 
any o f the usual pharmaceutical media may be employed, 
such as, for example, water, glycols, oils, alcohols, flavoring 
agents, preservatives, coloring agents, suspending agents, 
and the like in the case o f oral liquid preparations (such as, 
for example, suspensions, elixirs and solutions); or carriers 
such as starches, sugars, diluents, granulating agents, lubri­
cants, binders, disintegrating agents and the like in the case 
o f oral solid preparations (such as, for example, powders, 
capsules and tablets). Because o f their ease in administra­
tion, tablets and capsules represent the most advantageous 
oral dosage unit form, in which case solid pharmaceutical 
carriers are obviously employed. If  desired, tablets may be 
sugar-coated or enteric-coated by standard techniques. The 
active agent can be encapsulated to make it stable to passage 
through the gastrointestinal tract while at the same time 
allowing for passage across the blood brain barrier. See for 
example, WO 96/11698.
[0066] For parenteral administration, the compound may 
be dissolved in a pharmaceutical carrier and administered as 
either a solution or a suspension. Illustrative of suitable 
carriers are water, saline, dextrose solutions, fructose solu­
tions, ethanol, or oils o f animal, vegetative or synthetic 
origin. The carrier may also contain other ingredients, for 
example, preservatives, suspending agents, solubilizing 
agents, buffers and the like. W hen the compounds are being 
administered intrathecally, they may also be dissolved in 
cerebrospinal fluid.
[0067] A  variety o f administration routes are available. 
The particular mode selected will depend o f course, upon the 
particular drug selected, the severity o f the disease state 
being treated and the dosage required for therapeutic effi­
cacy. The methods of this invention, generally speaking,
may be practiced using any mode o f administration that is 
medically acceptable, meaning any mode that produces 
effective levels o f the active compounds without causing 
clinically unacceptable adverse effects. Such modes o f 
administration include oral, rectal, sublingual, topical, nasal, 
transdermal or parenteral routes. The term “parenteral” 
includes subcutaneous, intravenous, epidural, irrigation, 
intramuscular, release pumps, or infusion.
[0068] For example, administration o f the active agent 
according to this invention may be achieved using any 
suitable delivery means, including:
[0069] (a) pump (see, e.g., Luer & Hatton (1993), Zirnm 
et al. (1984) and Ettinger et al. (1978));
[0070] (b), microencapsulation (see, e.g., U.S. Pat. Nos. 
4,352,883; 4,353,888; and 5,084,350);
[0071] (c) continuous release polymer implants (see, e.g., 
U.S. Pat. No. 4,883,666);
[0072] (d) macroencapsulation (see, e.g., U.S. Pat. Nos. 
5,284,761, 5,158,881, 4,976,859 and 4,968,733 and pub­
lished PCT patent applications W 092/19195, WO 
95/05452);
[0073] (e) naked or unencapsulated cell grafts to the CNS 
(see, e.g., U.S. Pat. Nos. 5,082,670 and 5,618,531);
[0074] (f) injection, either subcutaneously, intravenously, 
intra-arterially, intramuscularly, or to other suitable site; or
[0075] (g) oral administration, in capsule, liquid, tablet, 
pill, or prolonged release formulation.
[0076] In one embodiment o f this invention, an active 
agent is delivered directly into the CNS, preferably to the 
brain ventricles, brain parenchyma, the intrathecal space or 
other suitable CNS location, most preferably intrathecally.
[0077] Alternatively, targeting therapies may be used to 
deliver the active agent more specifically to certain types o f 
cell, by the use o f targeting systems such as antibodies or 
cell specific ligands. Targeting may be desirable for a variety 
o f reasons, e.g. if  the agent is unacceptably toxic, or if  it 
would otherwise require too high a dosage, or if  it would not 
otherwise be able to enter the target cells.
[0078] The active agents, which are peptides, can also be 
administered in a cell based delivery system in which a DNA 
sequence encoding an active agent is introduced into cells 
designed for implantation in the body of the patient, espe­
cially in the spinal cord region. Suitable delivery systems are 
described in U.S. Patent No. 5,550,050 and published PCT 
Application Nos. WO 92/19195, WO 94/25503, WO 
95/01203, WO 95/05452, WO 96/02286, WO 96/02646, 
WO 96/40871, WO 96/40959 and WO 97/12635. Suitable 
DNA sequences can be prepared synthetically for each 
active agent on the basis o f the developed sequences and the 
known genetic code.
[0079] The active agent is preferably administered in an 
therapeutically effective amount. By a “therapeutically 
effective amount” or simply “effective amount” o f an active 
compound is meant a sufficient amount o f the compound to 
treat the desired condition at a reasonable benefit/risk ratio 
applicable to any medical treatment. The actual amount 
administered, and the rate and time-course o f administration, 
will depend on the nature and severity o f the condition being
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treated. Prescription o f treatment, e.g. decisions on dosage, 
timing, e tc , is within the responsibility o f general practitio­
ners or spealists, and typically takes account o f the disorder 
to be treated, the condition o f the individual patient, the site 
o f delivery, the method o f administration and other factors 
known to practitioners. Examples o f  techniques and proto­
cols can be found in Rem ington’s P harm aceutical Sciences.
[0080] Dosage may be adjusted appropriately to achieve 
desired drug levels, locally or systemically. Typically the 
active agents o f the present invention exhibit their effect at 
a dosage range from about 0.001 mg/kg to about 250 mg/kg, 
preferably from about 0.01 mg/kg to about 100 mg/kg of the 
active ingredient, more preferably from a bout 0.05 mg/kg to 
about 75 mg/kg. A  suitable dose can be administered in 
multiple sub-doses per day. Typically, a dose or sub-dose 
may contain from about 0.1 mg to about 500 mg o f the active 
ingredient per unit dosage form. A more preferred dosage 
will contain from about 0.5 mg to about 100 mg o f active 
ingredient per unit dosage form. Dosages are generally 
initiated at lower levels and increased until desired effects 
are achieved. In the event that the response in a subject is 
insufficient at such doses, even higher doses (or effective 
higher doses by a different, more localized delivery route) 
may be employed to the extent that patient tolerance permits. 
Continuous dosing over, for example 24 hours or multiple 
doses per day are contemplated to achieve appropriate 
systemic levels o f compounds.
[0081] Advantageously, the compositions are formulated 
as dosage units, each unit being adapted to supply a fixed 
dose o f active ingredients. Tablets, coated tablets, capsules, 
ampoules and suppositories are examples o f dosage forms 
according to the invention.
[0082] It is only necessary that the active ingredient con­
stitute an effective amount, i.e., such that a suitable effective 
dosage will be consistent with the dosage form employed in 
single or multiple unit doses. The exact individual dosages, 
as well as daily dosages, are determined according to 
standard medical principles under the direction o f a physi­
cian or veterinarian for use humans or animals.
[0083] The pharmaceutical compositions will generally 
contain from about 0.0001 to 99 wt. %, preferably about 
0.001 to 50 wt. %, more preferably about 0.01 to 10 wt. % 
o f the active ingredient by weight o f the total composition. 
In addition to the active agent, the pharmaceutical compo­
sitions and medicaments can also contain other pharmaceu­
tically active compounds. Examples o f other pharmaceuti­
cally active compounds include, but are not limited to, 
analgesic agents, cytokines and therapeutic agents in all o f 
the major areas o f clinical medicine. When used with other 
pharmaceutically active compounds, the conopeptides o f the 
present invention may be delivered in the form o f drug 
cocktails. A  cocktail is a mixture o f any one o f the com­
pounds useful with this invention with another drug or agent. 
In this embodiment, a common administration vehicle (e.g., 
pill, tablet, implant, pump, injectable solution, etc.) would 
contain both the instant composition in combination supple­
mentary potentiating agent. The individual drugs o f the 
cocktail are each administered in therapeutically effective 
amounts. A  therapeutically effective amount will be deter­
mined by the parameters described above; but, in any event, 
is that amount which establishes a level o f the drugs in the 
area o f body where the drugs are required for a period of 
time which is effective in attaining the desired effects.
[0084] Since the P-Superfamily conopeptides cause spas­
tic or spasmotic responses in mice, these peptides are useful 
for screening drugs for anti-convulsant activity. In accor­
dance with one embodiment o f this aspect o f the invention, 
a drug candidate and a P-Superfamily conopeptide are 
administered to a mouse and the response is monitored. If  
the drug candidate prevents a spastic or spasmotic response 
normally seen with the administration o f the P-Superfamily 
conopeptide, then the drug has anticonvulsant activity and 
can be used to treat convulsions, including epilepsy.
[0085] The practice o f the present invention employs, 
unless otherwise indicated, conventional techniques o f 
chemistry, molecular biology, microbiology, recombinant 
DNA, genetics, immunology, cell biology, cell culture and 
transgenic biology, which are within the skill o f the art. See, 
e.g., Maniatis et a l ,  1982; Sambrook et a l,  1989; Ausubel 
et a l,  1992; Glover, 1985; Anand, 1992; Guthrie and Fink, 
1991; Harlow and Lane, 1988; Jakoby and Pastan, 1979; 
Nucleic A cid  H ybridization  (B. D. Hames & S. J. Higgins 
eds. 1984); Transcription A nd Translation (B. D. Hames & 
S. J. Higgins eds. 1984); Culture O f  Anim al Cells (R. I. 
Freshney, Alan R. Liss, In c , 1987); Im m obilized Cells And  
Enzymes (IRL Press, 1986); B. Perbal, A P ractical Guide To 
M olecular Cloning (1984); the treatise, M ethods In Enzy- 
mology (Academic Press, In c , N.Y.); Gene Transfer Vectors 
F or M ammalian Cells (J. H. Miller and M. P. Calos eds, 
1987, Cold Spring Harbor Laboratory); M ethods In Enzy- 
m ology, Vols. 154 and 155 (Wu et al. eds.), Immunochemical 
M ethods In C ell A nd M olecular B iology  (Mayer and Walker, 
ed s. Academic Press, London, 1987); H andbook O f  Experi­
m ental Immunology, Volumes I-IV (D. M. Weir and C. C. 
Blackwell, ed s , 1986); Riott, Essential Immunology, 6th 
Edition, Blackwell Scientific Publications, Oxford, 1988; 
Hogan et a l .  Manipulating the Mouse Embryo, (Cold Spring 
Harbor Laboratory Press, Cold Spring Harbor, N .Y , 1986).
EXAMPLES
[0086] The present invention is further detailed in the 
following Examples, which are offered by way o f illustration 
and are not intended to limit the invention in any manner. 
Standard techniques well known in the art or the techniques 
specifically described below are utilized.
Example 1 
Methods
[0087] Purification o f the Spasmodic Peptide. The spas­
modic peptide was purified from C. textile venom by two 
different methods:
[0088] Purification L Freeze-dried C. textile venom was 
extracted with 0.2 M ammonium acetate and then fraction­
ated in a Bio-Gel column as described by Hillyard et al. 
(1989). The spasmodic peptide and the previously described 
King Kong peptide (8-conotoxin TxVIA) came from the 
same size fraction. An early peak was chromatographed on 
a Vydac reverse-phase C 18 column using a gradient o f 
acetonitrile (ACN) in 0.1% trifiuoracetic acid (TFA). The 
resulting major peak was rerun on the same column-buffer 
system to obtain the pure peptide, which was reduced and 
alkylated and used for amino acid sequence analysis.
[0089] Purification II. Lyophilized C. textile  venom from 
specimens collected in the Philippines (125 mg) was
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extracted sequentially with 10 mL each o f H 20, 20% ACN, 
40% ACN, 60% ACN, and 90% ACN. The mixture was 
sonicated for three 30-s periods over ice water and centri­
fuged at 5000 g for 5 min; the supernatants were stored at 
-20° C. The crude venom extract was applied to a prepara­
tive scale reversed-phase HPLC; the extract (20 mL) was 
diluted to 350 mL with 0.1% TFA solution and applied to a 
C 18 Vydac preparative column (22.0x250 mm). Fractions 
were eluted at 20 mL/min with a linear gradient o f 0.1% TFA 
in water and 0.09% TFA in 60% acetonitrile. Further puri­
fication o f the peptide used C 18 Microsorb MV and C 18 
Vydac analytical columns at a gradient o f 0.23% acetoni- 
trile/min and a flow rate o f 1 mL/min. The effluents were 
monitored at 220 nm, fractions were collected in polypro­
pylene tubes, and aliquots were assayed for biological 
activity.
[0090] Reduction and Alkylation. The purified peptide 
(1.2 nmol) was reduced with dithiothreitol (DTT) and alky­
lated with 4-vinylpyri dine. The pH o f the peptide solution 
was adjusted to 8 with 0.5 M tris(hydroxymethyl)amino 
methane, and DTT was added to a final concentration o f 10 
mM. The solution was flushed with nitrogen, incubated at 
65° C. for 15 min, and cooled to room temperature. Five 
microliters o f 4-vinylpyridine was added per milliliter o f 
solution; the mixture was left in the dark at room tempera­
ture for 25 min and then diluted with 500 (xL o f 0.1% TFA. 
The mixture was applied on an analytical C 18 Microsorb MV 
HPLC column, which was eluted using 0.1% TFA and 
0.085% TFA in 90% acetonitrile (B90) as limiting buffers. 
The alkylated peptide was recovered by first eluting the 
column for 50 min with 12% buffer B90 to remove most o f 
the reaction byproducts before applying a gradient o f 
12-90% buffer B90 over 78 min at a flow rate o f 1 mL/min. 
A  blank reaction (without peptide) was run on HPLC for 
comparison.
[0091] Sequencing. The alkylated peptide (300 pmol) was 
sequenced by standard Edman methods using Applied Bio­
system model 492 sequenator (DNA/Peptide Facility, Uni­
versity o f Utah). The 3-phenyl-2-thiohydantoin derivatives 
were identified by HPLC. The sequence was confirmed by 
mass spectrometry.
[0092] Cloning the Spasmodic Peptide. On the basis o f the 
amino acid sequence o f the isolated spasmodic peptide from 
C. textile, oligonucleotide primers were designed for PCR 
amplification o f the corresponding cDNA from a direction­
ally cloned cDNA library (Woodward et a l ,  1990). Three 
oligonucleotide primers with degenerate nucleotide 
sequences were synthesized.
Primer 1,
5 ' CCR TTI ACI GCI CCR CAI CC 3 ';  (SEQ ID NO: 12) 
primer 2,
5 ' TGR CAI SWR TTR TTR CAI CC 3 ';  (SEQ ID NO: 13) 
and
primer 3,
ATR CAR TGI SWY TCR CAR TC 3' (SEQ ID NO: 14)
(where l=inosine, R=A and G, Y=C and T, S=G and C, and 
W=A and T) represent sequences complementary to the 
coding sequences at the C-terminus, central, and N-terminus 
o f the peptide, respectively. Primary amplification was car­
ried out using a vector-specific 5' oligonucleotide and primer 
1 in a 1605 Air Thermo-Cycler (Idaho Technology, Idaho 
Falls, Id.). The product was reamplified using the 5' vector- 
specific primer and primer 2 and then electrophoresed on an 
agarose gel. The major product isolated using Qiaquick gel 
extraction kit (Qiagen, Valencia, Calif.) was ligated to 
pGEM-T vector DNA (Promega, Madison, Wis.) and used to 
transform Escherichia coli DH5R. The nucleic acid 
sequence of DNA inserted into pGEM-T was determined at 
the DNA Sequenc-ing Facility at the University o f Utah. An 
oligonucleotide primer corresponding to 5' sequences was 
thus obtained, and a vector-specific 3' primer was used to 
PCR amplify the entire clone. The amplified DNA was 
cloned and sequenced. The entire sequence o f spasmodic 
cDNA was assembled from the overlapping sequences and 
is predicted to contain the amino acid sequence o f the mature 
spasmodic toxin.
[0093] cDNA corresponding to the spasmodic peptide 
from C. gloriam aris was obtained by PCR amplification o f 
DNA isolated from a directionally cloned C. gloriam aris 
cDNA library. Oligonucleotide primers corresponding to the 
5' and the 3' untranslated regions o f the previously isolated 
C. textile  spasmodic peptide cDNA were used. The ampli­
fied DNA was cloned and its sequence determined as 
described above.
[0094] y-Glutamyl Carboxylase Assay. The peptide corre­
sponding to the -2 0  to -1  region o f the spasmodic peptide 
precursor, linked at its C-terminus to the pentapeptide 
FLEEL-NH (SEQ ID NO: 15), was synthesized by Dr. R. 
Schackmann, DNA Peptide Facility, Huntsman Cancer Cen­
ter, University o f Utah. The identity o f the peptide was 
confirmed using ESI-MS. Partially purified y-carboxy- 
glutamate carboxylase was prepared as described by Stanley 
et al. (1997). The assay was carried out as described by 
Bandyopadhyay et al. (1998), except that the spasmodic 
peptide pro region (-20  to -1)-FLEEL-NH2 was used as the 
substrate for the reaction. Experiments were done in tripli­
cate, and the data were fit to a single-site binding model and 
analyzed using GraphPad Prism from GraphPad Software, 
Inc. (San Diego, Calif.).
[0095] Bioassay. The biological activity of the peptide was 
determined using 9-15-day-old mice. Approximately 5-290 
pmol (per gram body weight) o f the lyophilized samples 
dissolved in normal saline solution were injected i.e. (intrac­
erebral) into mice. Control mice were injected with equal 
volume o f normal saline solution containing dissolved resi­
due (if any) o f the corresponding lyophilized column buffer. 
After injection, the mice were returned to their cages and 
observed for the onset o f any abnormal behavior.
[0096] Siamese fighting fish were injected in the dorsal 
muscle with 10 (xL o f the saline solution of the peptide and 
observed for suppression o f aggressive behavior when 
placed in mirrored aquaria. Likewise, control fish were 
injected with normal saline solution using 26-gauge insulin 
syringes. Each fish was observed for I h or longer depending 
on the activity.
Example 2
Purification of the Spasmodic Peptide.
[0097] The spasmodic peptide was initially detected as an 
early-eluting major peak from crude Conus textile  venom,
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which was notable for a characteristic suite o f symptoms 
observed after i.e. injection into mice. Within a certain dose 
range, injected mice were hypersensitive to sensory input 
and, when either touched or exposed to auditory stimulation, 
became hyperexcitable to the point where seizure-like symp­
toms could be induced. Since this symptomatology is char­
acteristic o f mutant mice strains carrying either the spas­
modic or spastic mutation, we trivially refer to this peptide 
as the “spasmodic peptide” . The peptide was identified 
through the various purification steps by following the 
spasmodic symptomatology described above.
[0098] W hen the purified peptide was injected into mice, 
even a dose o f =10 pmol/g was sufficient to induce running 
in circles and hyperactivity. At higher doses (50 pmol/g), the 
mice exhibited running and climbing symptoms for close to 
1 h. Between 130 and 150 pmol/g, characteristic “spas­
modic” symptomatology was elicited. A  hand clap would 
make mice jump high and start running rapidly. When 
exposed to a loud hand clap, or if  the cage cover were 
dropped, the mice lost motor control and exhibited seizure­
like symptoms from which they eventually recovered. At the 
highest doses tested (>250 pmol/g body weight), after the 
characteristic spas-modic symptomatology, lethality 
occurred. Injection o f a similar dose range intramuscularly 
into fish elicited no unusual symptomatology.
Example 3
Biochemical Characterization o f the Spasmodic 
Peptide; cDNA Cloning
[0099] The amino acid sequence o f two batches o f purified 
peptide was determined using standard Edman chemistry. 
Purified peptide was reduced and alkylated, and a single 
unequivocal sequence could be assigned through 27 Edman 
steps, except that no assignment could be made for positions 
8 and 13: GCNNSCQXHSDCXSHCICTFRGCGAVN 
(SEQ ID NO: 16, where X meant no assignment could be 
made). However, a trace o f Glu was detected at the two 
unassigned positions, characteristic o f residues that have 
been posttranslationally modified from glutamate to y-car- 
boxyglutamate. The presence o f y-carboxyglutamate in the 
peptide was directly confirmed by alkaline hydrolysis as 
previously described (McIntosh et a l ,  1984).
[0100] To definitively establish the sequence of the spas­
modic peptide, a cDNA clone encoding the spasmodic 
peptide was identified and characterized from a Conus 
textile  library (Woodward et a l,  1990), and a mass spectro- 
metric analysis was carried out. The data in Table 1 show the 
predicted sequence for the open reading frame from the 
cDNA clone. This sequence corresponds with amino acid 
sequence analysis, except for positions 8 and 13 where the 
cDNA sequence predicts a glutamate residue at both posi­
tions, consistent with positions 8 and 13 being y-carboxy- 
glutamate (Gla) in the mature gene product. The cDNA 
sequence also predicts that the C-terminal asparagine is 
amidated (since the C-terminal glycine o f the spasmodic 
peptide precursor would be processed to give an amidated 
C-terminus in the mature peptide). All o f the data taken 
together are consistent with the following sequence assign­
ment for the spasmodic peptide:
[0101] Also consistent with the sequence assignment 
above are the mass spectrometry analyses. Using LDMS, a
value of 2955.1 was obtained; an electrospray determination 
gave a mass o f 2955.0. The predicted mass o f the mature 
peptide shown above is 2955.03.
Example 4
Evidence for a y-CRS Sequence in the the 
Spasmodic Peptide
[0102] The presence o f y-carboxyglutamate in the spas­
modic peptide suggests that a y-CRS is docking the y-car- 
boxylase enzyme at a site N-terminal to the glutamate 
residues to be posttranslationally modified. It was previously 
established that the -1 to -2 0  region of the conantokin-G 
precursor (another y-carboxylated conopeptide) contains 
functional recognition signal sequences (Bandyopadhyay et 
a l,  1998). To test whether the spasmodic peptide precursor 
from C. textile  similarly contains a y-carboxylation recog­
nition signal sequence in its -1  to -2 0  region, a peptide 
chimera was synthesized. The -1  to -2 0  region from the 
spasmodic peptide precursor was attached to a model y-car- 
boxylation substrate FLEEL (SEQ ID NO: 15). FLEEL (SEQ 
ID NO: 15), initially designed as a substrate for mammalian 
y-glutamyl carboxylase (Suttie et a l ,  1979), has previously 
been used for the study o f Conus carboxylase (Stanley et al., 
1997; Bandyopadhyay et a l ,  1998; Haushka et a l ,  1988; 
Czerwiec et a l,  1996). The y-carboxylation o f FLEEL (SEQ 
ID NO: 15) could then be assessed in the absence and 
presence o f the -1  to -2 0  region of the spasmodic peptide. 
Clearly, the presence o f the -1  to -2 0  spasmodic peptide 
region does indeed increase the affinity for the targeted 
FLEEL (SEQ ID NO: 15) sequence by over 30-fold. The 
estimated apparent Kmvalues in the absence and presence o f 
propeptide are 1 .4xl0-4 and 4 .7x l0 -6 M, respectively. 
These results provide evidence for a y-CRS in the propeptide 
region o f the spasmodic peptide precursor.
Example 5
A Conotoxin Related to the Spasmodic Peptide 
from Conus gloriam aris
[0103] In an attempt to characterize other potential mem­
bers o f the spasmodic peptide family, an analysis o f other 
Conus species for cDNA clones related to the spasmodic 
peptide precursor was carried out. The predicted amino acid 
sequence o f an open reading frame in a cDNA clone from 
another molluscivorous Conus species, C. gloriam aris, is 
also shown in Table 1.
[0104] The putative sequence o f the Conus gloriam aris 
peptide exhibits a striking level o f sequence identity to the 
spasmodic peptide from C. textile. However, in Conus 
gloriam aris peptide the two y-carboxyglutamates o f the 
spasmodic peptide o f C. textile are mutated to serine and 
alanine. Functional differences between the two peptides 
have not yet been defined, since the peptide from neither C. 
textile nor C. gloriam aris has been successfully chemically 
synthesized. However, the results so far indicate that the 
spasmodic peptide family may be a particularly favorable 
group to investigate structure/function for peptides contain­
ing y-carboxyglutamate residues.
Example 6
[0105] Isolation of DNA Encoding P-Superfamily 
Conopeptides
[0106] DNA coding for conotoxin peptides was isolated 
and cloned in accordance with conventional techniques
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using general procedures well known in the art, such as 
described in Olivera et al. (1996), including using primers 
based on the DNA sequence o f P-superfamily conopeptides. 
Alternatively, cDNA libraries were prepared from Conus 
venom duct using conventional techniques. DNA from 
single clones was amplified by conventional techniques 
using primers which correspond approximately to the M l 3 
universal priming site and the M l 3 reverse universal
priming site. Clones having a size o f approximately 300-500 
nucleotides were sequenced and screened for similarity in 
sequence to known conotoxins. The DNA sequences and 
encoded propeptide sequences are set forth in Table 1. DNA 
sequences coding for the mature toxin can also be prepared 
on the basis o f the DNA sequences set forth in Table 1. An 
alignment o f the conopeptides o f the present invention is set 
forth in Table 2.
TABLE 1
(SEQ ID NO: 17)
Name: Af9.1
Species: ammiralis 











T ra n s la tio n :
MHLSLARSAVLMLLLLFALGNFWVQSGQITRDVDNGQLTDNRRNLQSKWKPVSLFMSRR
SCNNSCNEHSDCESHCICTFSGCKIILI
(SEQ ID NO: 18)
Toxin Sequence:
Ser-Cys-Asn-Asn-Ser-Cys-Asn-Xaal-His-Ser-Asp-Cys-Xaal-Ser-His- (SEQ ID NO: 2)
C ys-Ile-C ys-T hr-Phe-Ser-G ly-C ys-L ys-Ile-Ile-L eu-Ile-
Name: Af9.2
Species: ammiralis











T ra n s la tio n :
MHLSLARLAVLMLLLLFALGNFWVQSGQITRDVDNGQLTDNRRNLQSKWKPVSLFMSRR
(SEQ ID NO: 19)
(SEQ ID NO: 20)
SCNNSCNEHSDCESHCICTFRGCGAVNG
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T A B L E  1 - c o n t i n u e d
Toxin Sequence:
Ser-Cys-Asn-Asn-Ser-Cys-Asn-Xaal-His-Ser-Asp-Cys-Xaal-Ser-His- (SEQ ID NO: 3)
Cys-Ile-Cys-Thr-Phe-Arg-Gly-Cys-Gly-Ala-Val-Asn-#
Name: Ca9.1
Species: c a ra c te r is t ic u s  
Iso la te d : No 
Cloned: Yes 
DNA Sequence:








T ra n s la tio n :
MHLSLARSAVLMLLLLFALDNFVGVQPGQITRDVDNRRNRQSRWKPRSLFKSLHKRASCG (SEQ ID NO: 22)
GTCTESADCPSTCSTCLHAQCEST
Toxin Sequence:
Ala-Ser-Cys-Gly-Gly-Thx-Cys-Thr-Xaal-Ser-Ala-Asp-Cys-Xaa3-Ser- (SEQ ID NO: 4)
Thr-Cys-Ser-Thr-Cys-Leu-His-Ala-Gln-Cys-Xaal-Ser-Thr-
Name: Ca9.2
Species: c a ra c te r is t ic u s
Iso la te d : No
Cloned: Yes
DNA Sequence:








T ra n s la tio n :
MHLSLARSAVLMLLLLFALDNFVGVQPGQITRDVDNRRNLQSRWKPRSLFKSLHKRASCG (SEQ ID NO: 24)
GTCTESADCPSTCSTCLHAQCE
Toxin Sequence:
Ser-Cys-Gly-Gly-Thr-Cys-Thr-Xaal-Ser-Ala-Asp-Cys-Xaa3-Ser-Thr- (SEQ ID NO: 5)
Cys-Ser-Thr-Cys-Leu-His-Ala-Gln-Cys-Xaal-
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T A B L E  1 - c o n t i n u e d
Name: Cn9.1
Species: consors 
Iso la te d : No 
Cloned: Yes 
DNA Sequence:








T ra n s la tio n :
MLLLLFALGIFVGVQPEQITRDVDKGYSTDDGHDLLSLLKQISLRACTGSCNSDSECYNFCD (SEQ ID NO: 26)
CIGTRCEAQK
Toxin Sequence:
Ala-Cys-Thr-Gly-Ser-Cys-Asn-Ser-Asp-Ser-Xaal-Cys-Xaa5-Asn-Phe- (SEQ ID NO: 6)
Cys-Asp-Cys-Ile-Gly-Thr-Arg-Cys-Xaal-Ala-Gln-Lys-
Name: Gm9.1
Species: g lo riam aris
Iso la te d : No
Cloned: Yes
DNA Sequence:








T ra n s la tio n :
MHLSLARSAVLMLLLLFALGNFVWQSGLITRDVDNGQLTDNRRNLQTEWNPLSLFMSRRS (SEQ ID NO: 28)
CNNSCQSHSDCASHCICTFRGCGAVNG
Toxin Sequence:
Ser-Cys-Asn-Asn-Ser-Cys-Gln-Ser-His-Ser-Asp-Cys-Ala-Ser-His-Cys- (SEQ ID NO: 7) 
Ile-Cys-Thr-Phe-Arg-Gly-Cys-Gly-Ala-Val-Asn-#
Name: Im9.1
Species: im p e ria lis  
Iso la te d : No
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Cloned: Yes 
DNA Sequence:









T ra n s la tio n :
MHLSLASSAALMLLLLFALGNFVGVQPGQIRDLNKGQLKDNRRNLQSQRKQMSLLKSLHD (SEQ ID NO: 30)
RNGCNGNTCSNSPCPNNCYCDTEDDCHPDRREH
Toxin Sequence:





Iso la te d : No
Cloned: Yes
DNA Sequence:








T ra n s la tio n :
MLLLLFALGSFVWQSGQITRDVDNGQLADNRRTLRSQWKQVSFFKSLDKRLTCNDPCQM (SEQ ID NO: 32)
HSDCGICECVENKCIFFM
Toxin Sequence:
Leu-Thr-Cys-Asn-Asp-Xaa3-Cys-Gln-Met-His-Ser-Asp-Cys-Gly-lle- (SEQ ID NO: 9)
Cys-Xaal-Cys-Val-Xaal-Asn-Lys-Cys-Ile-Phe-Phe-M et-
Name: tx9a (Tx9.1)
Species: t e x t i l e  
Iso la te d : Yes 
Cloned: Yes
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DNA Sequence:














T ra n s la tio n :
MHLSLARSAVLMLLLLFALGNFVWQSGQITRDVDNGQLTDNRRNLQSKWKPVSLYMSRR (SEQ ID NO: 3
GCNNSCQEHSDCESHCICTFRGCGAVNG
Toxin Sequence:
Gly-Cys-Asn-Asn-Ser-Cys-Gln-Xaal-His-Ser-Asp-Cys-Xaal-Ser-His- (SEQ ID NO: 1
Cys-Ile-Cys-Thr-Phe-Arg-Gly-Cys-Gly-Ala-Val-Asn-#
Name: U0 30
Species: t e x t i l e  
Iso la te d : Yes 
Cloned: No 
DNA Sequence:
T ra n s la tio n :
Toxin Sequence:
Gly-Cys-Asn-Asn-Ser-Cys-Gln-Xaal-His-Ser-Asp-Cys-Xaal-Ser-His- (SEQ ID NO: 1
Cys-Ile-Cys-Thr-Ser-Arg-Gly-Cys-Gly-Ala-Val-Asn-#
Xaal i s  Glu or Y-c a rkoxy-Glu 
Xaa3 i s  Pro or hydroxy-Pro
Xaa5 i s  Tyr, 125I-T yr, mono-iodo-Tyr, d i-iodo-T yr, O-sulpho-Tyr or O-phospho-Tyr 
a i s  fre e  carboxyl or amidated C-term inus, p re fe rab ly  free  carboxyl 
# i s  fre e  carboxyl or amidated C-term inus, p re fe rab ly  amidated
[0107]




Af9 .1 S-CN-NSCNEHSDCESHCI-C- (SEQ ID NO: 2) 
TFSGCKII—L I12
Ca9 .1 ASCGG-TCTESADCPSTCSTC- (SEQ ID NO: 4) 
LHAQCEST~
Af9 . 2 S-CN-NSCNEHSDCESHCI-C- (SEQ ID NO: 3) 
TFRGCGAV—N#
Ca9 .2 S-CGG-TCTESADCPSTCSTC- (SEQ ID NO: 5) 
LHAQCE~
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(SEQ ID NO: 6)
Im9.1 NGCNGNTCSNSP-CPNNCY-
cdteddchpdrreh”
(SEQ ID NO: 8)
Pn9.1 LTCN-DPCQMHSDC-GICE-C-
venkciffm”
(SEQ ID NO: 9)
U030 G-CN-NSCQXHSDCXSHCI-C- 
TSRGCGAV—N#
(SEQ ID NO: 11)
Tx9.1 G-CN-NSCQXHSDCXSHCI-C- 
TFRGCGAV—N#
(SEQ ID NO: 10)
Gm9.1 S-CN-NSCQSHSDCASHCI-C- 
TFRGCGAV—N#
(SEQ ID NO: V)
X is  Glu or Gla.
[0108] It w ill be appreciated that the m ethods and com ­
positions o f  the instant invention can  be incorporated in the 
form  o f  a variety  o f  em bodim ents, only a few  o f  w hich  are 
d isclosed herein. It w ill be apparent to the artisan that o ther 
em bodim ents exist and do no t depart from  the spirit o f  the 
invention. Thus, the described em bodim ents are illustrative 
and should not be  construed as restrictive.
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SEQUENCE LISTING
<160> NUMBER OF SEQ ID NOS: 34
<210> SEQ ID NO 1
<2 11> LENGTH: 34
<212> TYPE: PRT
<213> ORGANISM: A rtific ia l
<220> FEATURE:
<223> OTHER INFORMATION: Generic P-Superfamily Conopeptides 
<220> FEATURE:
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: (1 ) . .(5 )
<223> OTHER INFORMATION: Xaa a t  res idue  1 may be Ser, Ala, Asn, Leu,
Thr, Gly, g-Thr (g i s  glycan) or g -Ser; Xaa a t  res idue  2 may be 
des-Xaa, Ser, Thr, Gly, g-Thr or g -Ser; Xaa a t  res idue  4 may be 
Asn, Gin, Gly, Thr, Ser, g-Thr or g-Ser; Xaa a t  res idue  5 may be 
des-Xaa or 
<220> FEATURE:
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: (5 ) ..(1 0 )
<223> OTHER INFORMATION: Gly; Xaa a t  residue  6 may be des-Xaa, Asn or 
Asp; Xaa a t  res idue  7 may be Ser, Thr, Pro, Hyp (hydroxy-Pro), 
g-Thr or g-Ser; Xaa a t  res idue  9 may be Asn, Gin, Thr, Ser, g-Thr 
or g-Ser; Xaa a t  res idue  10 may be Glu, Ser, Asn, Met, Thr,
<220> FEATURE:
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: (1 0 ) ..(1 3 )
<223> OTHER INFORMATION: Gla (gamma-carboxy-Glu), Nle (n o rleu c in e ), Asp, 
Gin, g-Thr or g-Ser; Xaa a t  res idue  11 may be H is, Ser, Asp, Thr, 
g-Thr or g-Ser; Xaa a t  res idue  12 may be Ser, Ala, Pro, Hyp, Thr, 
g-Thr or g-Ser; Xaa a t  res idue  13 may be Asp, Glu, Gla or any 
<220> FEATURE:
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: (1 3 ) ..(1 5 )
<223> OTHER INFORMATION: sy n th e tic  ac id ic  amino ac id ; Xaa a t  residue  15 
may be des-Xaa, Glu, Asp, Pro, Hyp, Gla, Ala, Tyr, meta-Tyr, 
ortho-T yr, nor-Tyr, mono-halo-Tyr, d i-ha lo -T y r, O-sulpho-Tyr, 
O-phospho-Tyr, n itro -T y r or any sy n th e tic  ac id ic  amino acid ;
<220> FEATURE:
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: (1 6 ) ..(1 7 )
<223> OTHER INFORMATION: Xaa a t  res idue  16 may be Ser, Asn, Gly, Thr,
HyPf g-Thr, g-Ser or any sy n th e tic  hydroxy contain ing  amino ac id ; 
Xaa a t  res idue  17 may be His, Thr, Phe, Asn, l i e ,  Ser, Gin, g-Ser, 
g-Thr, any sy n th e tic  hydroxy contain ing  amino ac id , Trp (D or L), 
<220> FEATURE:
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: (1 7 ) ..(1 9 )
<223> OTHER INFORMATION: neo-Trp, halo-Trp (D or L) or any sy n the tic
arom atic amino ac id ; Xaa a t  res idue  19 may be l i e ,  Ser, Asp, Glu, 
Gla, any sy n th e tic  amino ac id , Thr, g-Ser, g-Thr, any sy n th e tic  
hydroxy contain ing  amino ac id , Tyr, meta-Tyr, ortho-T yr, nor-Tyr, 
<220> FEATURE:
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: (1 9 ) ..(2 2 )
<223> OTHER INFORMATION: mono-halo-Tyr, d i-ha lo -T y r, O-sulpho-Tyr,
O-phospho-Tyr or n ito r-T y r; Xaa a t  res idue  20 may be des-Xaa, Thr, 
Ser, g-Thr, g-Ser or any sy n th e tic  hydroxy contain ing  amino ac id ; 
Xaa a t  res idue  22 may be des-Xaa, Asp, Glu, Gla or any 
<220> FEATURE:
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: (2 2 ) ..(2 4 )
<223> OTHER INFORMATION: sy n th e tic  ac id ic  amino ac id ; Xaa a t  residue  23 
may be Thr, Leu, l i e ,  Val, Ser, g-Thr, g-Ser or any sy n th e tic  
hydroxy contain ing  amino ac id ; Xaa a t  res idue  24 may be Phe, His, 
Gly, Glu, Asp, Gla, any sy n th e tic  ac id ic  amino ac id , Ser, Thr, 
g -S e r,
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<220> FEATURE:
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: (24 ) . .  (25 )
<223> OTHER INFORMATION: g-Thr, any sy n th e tic  hydroxy contain ing  amino 
ac id , Trp (D or L), neo-Trp, halo-Trp (D or L) or any sy n the tic  
arom atic amino ac id ; Xaa a t  residue  25 may be Ser, Thr, Ala, Asp, 
Asn, Gin, g-Ser, g-Thr, His, Arg, o rn ith in e , homo-Lys, 
homoarginine,
<220> FEATURE:
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: (25 ) . .  (26 )
<223> OTHER INFORMATION: nor-Lys, N-methyl-Lys, N,N1-dim ethyl-L ys, N,N1, 
N '1-trim ethy l-L ys or any sy n th e tic  basic  amino ac id ; Xaa a t  
res idue  26 may be Gly, Gin, Asn, His, Arg, o rn ith in e , homo-Lys, 
homoarginine, nor-Lys, N-methyl-Lys, N,N1-dim ethyl-L ys,
<220> FEATURE:
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: (26 ) . .  (28 )
<223> OTHER INFORMATION: N ,N ',N ''-trim e th y l-L y s  or any sy n th e tic  basic  
amino ac id ; Xaa a t  residue  28 may be Gly, Glu, Asp, Gla, any 
sy n th e tic  a c id ic  amino ac id , l i e ,  H is, Arg, o rn ith in e , homo-Lys, 
homoarginine, nor-Lys, N-methyl-Lys, N,N1-dim ethyl-L ys,
<220> FEATURE:
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: (28 ) . .  (30 )
<223> OTHER INFORMATION: N ,N ',N ''-trim e th y l-L y s  or any sy n th e tic  basic  
amino ac id ; Xaa a t  residue  29 may be des-Xaa, l i e ,  Ala, Ser, Pro, 
Hyp, Phe, Thr, g-Thr, g-Ser or any sy n th e tic  hydroxy contain ing  
amino ac id ; Xaa a t  residue  30 may be des-Xaa, l i e ,  Val, Thr, Asp, 
<220> FEATURE:
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: (3 0 ) ..(3 1 )
<223> OTHER INFORMATION: Phe, Ser, g-Thr, g-Ser or any sy n th e tic  hydroxy 
contain ing  amino ac id ; Xaa a t  residue  31 may be des-Xaa, Met, Nle, 
His, Arg, o rn ith in e , homo-Lys, homoarginine, nor-Lys,
N-methyl-Lys, N,N' -dim ethyl-Lys, N,N' ,N11-trim ethy l-L ys or any 
sy n th e tic  
<220> FEATURE:
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: (3 1 ) ..(3 3 )
<223> OTHER INFORMATION: basic  amino ac id ; Xaa a t  res idue  32 may be 
des-Xaa, His, Arg, o rn ith in e , homo-Lys, homoarginine, nor-Lys, 
N-methyl-Lys, N,N' -fimethyl-Lys, N,N' , N11-trim ethy l-L ys or any 
sy n th e tic  basic  amino ac id ; Xaa a t  res idue  33 may be des-Xaa, Leu, 
Asn, Gin, Glu,
<220> FEATURE:
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: ( 33 ) . .  ( 34 )
<223> OTHER INFORMATION: Asp, Gla or any sy n th e tic  amino ac id ; Xaa a t 
res idue  34 may be des-Xaa, l i e ,  His, Arg, o rn ith in e , homo-Lys, 
homoarginine, nor-Lys, N-methyl-Lys, N,N' -dim ethyl-L ys, N,N' ,N' '  
-trim ethy l-L ys or any sy n th e tic  basic  amino ac id .
<400> SEQUENCE: 1
Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa
1 5  10 15
Xaa Cys Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa
<210> SEQ ID NO 2 
<2 11> LENGTH: 28 
<212> TYPE: PRT
<213> ORGANISM: Conus ammiralis 
<220> FEATURE:
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: ( 1) . . (28)
<223> OTHER INFORMATION: Xaa may be Glu or Gla 
<400> SEQUENCE: 2
S e r  C y s  A s n  A s n  S e r  C y s  A s n  X a a  H i s  S e r  A s p  C y s  X a a  S e r  H i s  C y s
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1 5  10 15
l i e  Cys Thr Phe Ser Gly Cys Lys l i e  l i e  Leu l i e  
20 25
<210> SEQ ID NO 3 
<2 11> LENGTH: 27 
<212> TYPE: PRT
<213> ORGANISM: Conus ammiralis 
<220> FEATURE:
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: ( 1) . . (27)
<223> OTHER INFORMATION: Xaa may be Glu or Gla 
<400> SEQUENCE: 3
Ser Cys Asn Asn Ser Cys Asn Xaa His Ser Asp Cys Xaa Ser His Cys
1 5  10 15
l i e  Cys Thr Phe Arg Gly Cys Gly Ala Val Asn 
20 25
<210> SEQ ID NO 4 
<2 11> LENGTH: 28 
<212> TYPE: PRT
<213> ORGANISM: Conus c a ra c te r is t ic u s  
<220> FEATURE:
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: ( 1) . . (28)
<223> OTHER INFORMATION: Xaa a t  res idues 9 and 26 may be Glu or Gla; Xaa 
a t  res idue  14 may be Pro or Hyp
<400> SEQUENCE: 4
Ala Ser Cys Gly Gly Thr Cys Thr Xaa Ser Ala Asp Cys Xaa Ser Thr
1 5  10 15
Cys Ser Thr Cys Leu His Ala Gin Cys Xaa Ser Thr 
20 25
<210> SEQ ID NO 5 
<2 11> LENGTH: 25 
<212> TYPE: PRT
<213> ORGANISM: Conus c a ra c te r is t ic u s  
<220> FEATURE:
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: ( 1) . . (25)
<223> OTHER INFORMATION: Xaa a t  res idues 8 and 25 may be Glu or Gla; Xaa 
a t  res idue  13 may be Pro or Hyp
<400> SEQUENCE: 5
Ser Cys Gly Gly Thr Cys Thr Xaa Ser Ala Asp Cys Xaa Ser Thr Cys
1 5  10 15
Ser Thr Cys Leu His Ala Gin Cys Xaa 
20 25
<210> SEQ ID NO 6
<2 11> LENGTH: 27
<212> TYPE: PRT
<213> ORGANISM: Conus consors
<220> FEATURE:
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: ( 1) . . (27)
<223> OTHER INFORMATION: Xaa a t  res idue  11 and 24 may be Glu or Gla; Xaa 
a t  res idue  13 may be Tyr, [125]l-Tyr, mono-iodo-Tyr, d i-iodo-T yr, 
O-sulpho-Tyr or O-phospho-Tyr
<400> SEQUENCE: 6
A l a  C y s  T h r  G l y  S e r  C y s  A s n  S e r  A s p  S e r  X a a  C y s  X a a  A s n  P h e  C y s
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1 5  10 15
Asp Cys l i e  Gly Thr Arg Cys Xaa Ala Gin Lys 
20 25
<210> SEQ ID NO 7 
<2 11> LENGTH: 27 
<212> TYPE: PRT
<213> ORGANISM: Conus g lo riam aris 
<400> SEQUENCE: 7
Ser Cys Asn Asn Ser Cys Gin Ser His Ser Asp Cys Ala Ser His Cys
1 5  10 15
l i e  Cys Thr Phe Arg Gly Cys Gly Ala Val Asn 
20 25
<210> SEQ ID NO 8 
<2 11> LENGTH: 32 
<212> TYPE: PRT
<213> ORGANISM: Conus im p e ria lis  
<220> FEATURE:
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: ( 1) . . (32)
<223> OTHER INFORMATION: Xaa a t  res idues 12, 14 and 27may be Pro or Hyp; 
Xaa a t  res idue  18 may be Tyr, [125]l-Tyr, mono-iodo-Tyr, d i- io d o - 
Tyr, O-sulpho-Tyr or O-phospho-Tyr; Xaa a t  res idues 22 and 
31 may be Glu or Gla
<400> SEQUENCE: 8
Asn Gly Cys Asn Gly Asn Thr Cys Ser Asn Ser Xaa Cys Xaa Asn Asn
1 5  10 15
Cys Xaa Cys Asp Thr Xaa Asp Asp Cys His Xaa Asp Arg Arg Xaa His 
20 25 30
<210> SEQ ID NO 9 
<2 11> LENGTH: 27 
<212> TYPE: PRT
<213> ORGANISM: Conus pennaceus 
<220> FEATURE:
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: ( 1) . . (27)
<223> OTHER INFORMATION: Xaa a t  res idue  6 may be Pro or Hyp; Xaa a t  
res idues 17 and 20 may be Glu or Gla
<400> SEQUENCE: 9
Leu Thr Cys Asn Asp Xaa Cys Gin Met His Ser Asp Cys Gly l i e  Cys 
1 5  10 15
Xaa Cys Val Xaa Asn Lys Cys l i e  Phe Phe Met
20 25
A O V SEQ ID NO 10
<2 11> LENGTH: 27
<2 12> TYPE: PRT
<2 13> ORGANISM: Conus t e x t i l e
<220> FEATURE:
A V NAME/KEY: PEPTIDE
<222> LOCATION: (1) . . (2 7 )
<223> OTHER INFORMATION: Xaa may be Glu or Gla
AooV SEQUENCE: 10
Gly Cys Asn Asn Ser Cys Gin Xaa His Ser Asp Cys Xaa Ser His Cys 
1 5  10 15
l i e  Cys Thr Phe Arg Gly Cys Gly Ala Val Asn 
20 25
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<210> SEQ ID NO 11
<2 11> LENGTH: 27
<212> TYPE: PRT
<213> ORGANISM: Conus t e x t i l e
<220> FEATURE:
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: ( 1) . . (27)
<223> OTHER INFORMATION: Xaa may be Glu or Gla 
<400> SEQUENCE: 11
Gly Cys Asn Asn Ser Cys Gin Xaa His Ser Asp Cys Xaa Ser His Cys
1 5  10 15
l i e  Cys Thr Ser Arg Gly Cys Gly Ala Val Asn 
20 25
<210> SEQ ID NO 12
<2 11> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: am plification primer
<220> FEATURE:
<221> NAME/KEY: m isc_feature
<222> LOCATION: (1) . . (20)
<223> OTHER INFORMATION: n i s  inosine
<400> SEQUENCE: 12
ccrttnacng  cnccrcancc
<210> SEQ ID NO 13 
<2 11> LENGTH: 20 
<212> TYPE: DNA
<213> ORGANISM: am plification primer 
<220> FEATURE:
<221> NAME/KEY: m isc_feature 
<222> LOCATION: ( 1) . . (20)
<223> OTHER INFORMATION: n i s  inosine
<400> SEQUENCE: 13
tg rcansw rt tr t t r c a n c c
<210> SEQ ID NO 14
<2 11> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: am plification primer
<220> FEATURE:
<221> NAME/KEY: m isc_feature
<222> LOCATION: (1) . . (20)
<223> OTHER INFORMATION: n i s  inosine
<400> SEQUENCE: 14 
a trc a r tg n s  w ytcrcartc
<210> SEQ ID NO 15
<2 11> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Conus t e x t i l e
<400> SEQUENCE: 15
Phe Leu Glu Glu Leu 
1 5
< 2 1 0 >  SEQ I D  NO 16
<2  1 1> LENGTH:  2 7
< 2 1 2 >  T Y P E :  PR T
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<213> ORGANISM: Conus t e x t i l e  
<220> FEATURE:
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: ( 1) . . (27)
<223> OTHER INFORMATION: Xaa i s  unknown
<400> SEQUENCE: 16
Gly Cys Asn Asn Ser Cys Gin Xaa His Ser Asp Cys Xaa Ser His Cys
1 5  10 15
l i e  Cys Thr Phe Arg Gly Cys Gly Ala Val Asn 
20 25
A O V SEQ ID NO 17
<2 11> LENGTH: 461
<2 12> TYPE: DNA
<2 13> ORGANISM: Conus ammiralis
<220> FEATURE:ACNCNV NAME/KEY: CDS
<222> LOCATION: (7) . . (270 )
AOOV SEQUENCE: 17
g ttaaa  a tg  c a t c tg  te a  c tg  gca ege te a  get g t t  t t g  atg  t t g  c t t  
Met His Leu Ser Leu Ala Arg Ser Ala Val Leu Met Leu Leu
1 5  10
c tg  c tg  t t t  gcc t t g  ggc aac t t t  g t t  gtg gtc cag te a  gga cag a ta  
Leu Leu Phe Ala Leu Gly Asn Phe Val Val Val Gin Ser Gly Gin l i e  
15 20 25 30
aca aga gat gtg gac aa t gga cag c tc  acg gac aac ege cg t aac ctg 
Thr Arg Asp Val Asp Asn Gly Gin Leu Thr Asp Asn Arg Arg Asn Leu
35 40 45
caa teg  aag tgg aag cca gtg ag t c tc  t t c  atg  te a  cga egg t e t  tg t  
Gin Ser Lys Trp Lys Pro Val Ser Leu Phe Met Ser Arg Arg Ser Cys
50 55 60
aac aa t t e t  tgc a a t gag ca t tc c  gat tgc gaa tc c  c a t t g t  a t t  tgc 
Asn Asn Ser Cys Asn Glu His Ser Asp Cys Glu Ser His Cys l i e  Cys 
65 70 75
acg t t t  age gga tgc aaa a t t  a t t  t t g  a ta  ta aa eg g a tt g a g tttg c tc  
Thr Phe Ser Gly Cys Lys l i e  l i e  Leu l i e
80 85
gtcaacaaga tg tcg cac ta  c a g c tc c tc t c tacag tg tg  taca tcgacc  aaacgacgca 
t c t t t t a t t t  c t t t g t c tg t  t g t a t t t g t t  t t c c tg t g t t  ca taacg tac  ag ag ccc ttt 
a a t t a c c t t t  a c tg c tc ttc  a c tta a c c tg  ataaccggaa ggtccagtgc t
<210> SEQ ID NO 18
<2 11> LENGTH: 88
<212> TYPE: PRT
<213> ORGANISM: Conus ammiralis
<400> SEQUENCE: 18
Met His Leu Ser Leu Ala Arg Ser Ala Val Leu Met Leu Leu Leu Leu
1 5  10 15
Phe Ala Leu Gly Asn Phe Val Val Val Gin Ser Gly Gin l i e  Thr Arg
20 25 30
Asp Val Asp Asn Gly Gin Leu Thr Asp Asn Arg Arg Asn Leu Gin Ser
35 40 45











S e r  C y s  A s n  G l u  H i s  S e r  A s p  C y s  G l u  S e r  H i s  C y s  l i e  C y s  T h r  P h e
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65 70 75 80
Ser Gly Cys Lys l i e  l i e  Leu l i e  
85
- c o n t i n u e d
A O V SEQ ID NO 19
<2 11> LENGTH: 459
<2 12> TYPE: DNA
<2 13> ORGANISM: Conus ammiralis
<220> FEATURE:ACNCNV NAME/KEY: CDS
<222> LOCATION: (7) . . (270 )
AOOV SEQUENCE: 19
g ttaaa  a tg  c a t c tg  te a  c tg  gca ege t t a  get g t t  t t g  atg  t t g  c t t  
Met His Leu Ser Leu Ala Arg Leu Ala Val Leu Met Leu Leu
1 5  10
c tg  c tg  t t t  gcc t t g  ggc aac t t t  g t t  gtg gtc cag te a  gga cag a ta  
Leu Leu Phe Ala Leu Gly Asn Phe Val Val Val Gin Ser Gly Gin l i e  
15 20 25 30
aca aga gat gtg gac aa t gga cag c tc  acg gac aac ege cg t aac ctg 
Thr Arg Asp Val Asp Asn Gly Gin Leu Thr Asp Asn Arg Arg Asn Leu
35 40 45
caa teg  aag tgg aag cca gtg ag t c tc  t t c  atg  te a  cga egg t c t  tg t  
Gin Ser Lys Trp Lys Pro Val Ser Leu Phe Met Ser Arg Arg Ser Cys
50 55 60
aac aa t t c t  tgc a a t gag ca t tc c  gat tgc gaa tc c  c a t t g t  a t t  tgc 
Asn Asn Ser Cys Asn Glu His Ser Asp Cys Glu Ser His Cys l i e  Cys 
65 70 75
acg t t t  aga gga tgc gga get g t t  a a t ggt tg a g t t tg e t  cgtcaacatg  
Thr Phe Arg Gly Cys Gly Ala Val Asn Gly
80 85
a tg tcg cac t acacactaca g c tc c tc tc t  acag tg tg ta  catcgaccaa acgacgcatc 
t t t t a t t t c t  t t g tc t g t t g  t g t t t g t t t t  c c tg tg ttc a  taacg tacag  ag c c c ttta a  
t t a c t t t t a c  tg c tc ttc a c  t ta a c c tg a t  aaccagaagg tcc a g tg c t
<210> SEQ ID NO 20
<2 11> LENGTH: 88
<212> TYPE: PRT
<213> ORGANISM: Conus ammiralis
<400> SEQUENCE: 20
Met His Leu Ser Leu Ala Arg Leu Ala Val Leu Met Leu Leu Leu Leu
1 5  10 15
Phe Ala Leu Gly Asn Phe Val Val Val Gin Ser Gly Gin l i e  Thr Arg
20 25 30
Asp Val Asp Asn Gly Gin Leu Thr Asp Asn Arg Arg Asn Leu Gin Ser
35 40 45
Lys Trp Lys Pro Val Ser Leu Phe Met Ser Arg Arg Ser Cys Asn Asn
50 55 60
Ser Cys Asn Glu His Ser Asp Cys Glu Ser His Cys l i e  Cys Thr Phe
65 70 75 80











< 2 1 0 >  SEQ I D  NO 2 1
<2  1 1> LENGTH:  4 2 2
< 2 1 2 >  T Y P E :  DNA
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<213> ORGANISM: Conus c a ra c te r is t ic u s  
<220> FEATURE:
<221> NAME/KEY: CDS 
<222> LOCATION: (7) . . (258 )
<400> SEQUENCE: 21
g ttaca  a tg  c a t c tg  te a  c tg  gca ege te a  get gtc t t g  atg  t t g  c t t  
Met His Leu Ser Leu Ala Arg Ser Ala Val Leu Met Leu Leu 
1 5  10
c tg  c tg  t t t  gcc t t g  gac aac t t c  g t t  ggg gtc cag cca gga cag a ta  
Leu Leu Phe Ala Leu Asp Asn Phe Val Gly Val Gin Pro Gly Gin l i e
15 20 25 30
aca aga gat gtg gac aac ege cg t aac egg caa teg  cga tgg aag cca 
Thr Arg Asp Val Asp Asn Arg Arg Asn Arg Gin Ser Arg Trp Lys Pro
35 40 45
agg ag t c tc  t t c  aag te a  c t t  c a t aaa cga gca teg  t g t  gga ggg ac t 
Arg Ser Leu Phe Lys Ser Leu His Lys Arg Ala Ser Cys Gly Gly Thr
50 55 60
tgc acg gaa ag t gcc gat tgc cc t tc c  acg tg t  ag t a c t tgc t t a  ca t 
Cys Thr Glu Ser Ala Asp Cys Pro Ser Thr Cys Ser Thr Cys Leu His
65 70 75
get caa tgc gag te a  aca tga tg tcg ca  c ta c a g c tc t tc tc ta c a g t 
Ala Gin Cys Glu Ser Thr
80
g tg taca tcg  accgtacgac g c a tc t t t ta  t t t c t t t g g c  t g t t t c a t t c  g t t t t c t t g t  
g ttc a ta a c a  tgcggagccc ttc c g tta c c  tc ta c tg c tc  ta c a c tta a c  c tgataacca  
gaaaatccag ta c t
<210> SEQ ID NO 22
<2 11> LENGTH: 84
<212> TYPE: PRT
<213> ORGANISM: Conus c a ra c te r is t ic u s
<400> SEQUENCE: 22
Met His Leu Ser Leu Ala Arg Ser Ala Val Leu Met Leu Leu Leu Leu
1 5  10 15
Phe Ala Leu Asp Asn Phe Val Gly Val Gin Pro Gly Gin l i e  Thr Arg
20 25 30
Asp Val Asp Asn Arg Arg Asn Arg Gin Ser Arg Trp Lys Pro Arg Ser
35 40 45
Leu Phe Lys Ser Leu His Lys Arg Ala Ser Cys Gly Gly Thr Cys Thr
50 55 60
Glu Ser Ala Asp Cys Pro Ser Thr Cys Ser Thr Cys Leu His Ala Gin
65 70 75 80
Cys Glu Ser Thr
<210> SEQ ID NO 23
<2 11> LENGTH: 426
<212> TYPE: DNA
<213> ORGANISM: Conus c a ra c te r is t ic u s
<220> FEATURE:
<221> NAME/KEY: CDS











g ttaca  a tg  c a t c tg  te a  c tg  gca ege te a  get g t t  t t g  atg  t t g  c t t  
Met His Leu Ser Leu Ala Arg Ser Ala Val Leu Met Leu Leu 
1 5  10
4 8
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c tg  c tg  t t t  gcc t t g  gac aac t t c  g t t  ggg gtc caa cca gga cag a ta  
Leu Leu Phe Ala Leu Asp Asn Phe Val Gly Val Gin Pro Gly Gin l i e
15 20 25 30
a c t aga gat gtg gac aac cgc cg t aac c tg  caa teg  cga tgg aag cca 
Thr Arg Asp Val Asp Asn Arg Arg Asn Leu Gin Ser Arg Trp Lys Pro
35 40 45
agg ag t c tc  t t c  aag te a  c t t  c a t aaa cga gca teg  t g t  gga ggg ac t 
Arg Ser Leu Phe Lys Ser Leu His Lys Arg Ala Ser Cys Gly Gly Thr
50 55 60
tgc acg gaa ag t gcc gat tgc cc t tc c  acg tg t  ag t a c t tgc t t a  ca t 
Cys Thr Glu Ser Ala Asp Cys Pro Ser Thr Cys Ser Thr Cys Leu His
65 70 75
get caa tgc gag tg aac a tg a t g tcgcactac a g c tc ttc tc  ta c a g tg tg t 
Ala Gin Cys Glu
80
acatcgaccg accgtacgac g c a tc t t t ta  t t t c t t t g t c  t g t t t c a t t c  g t t t t c t t g a  
g ttc a ta a c a  tgcggagccc ttc c g tta c c  tc ta c tg c tc  ta c a c tta a g  c tgataacca  
gaaaatccag ta c t
<210> SEQ ID NO 24
<2 11> LENGTH: 82
<212> TYPE: PRT
<213> ORGANISM: Conus c a ra c te r is t ic u s
<400> SEQUENCE: 24
Met His Leu Ser Leu Ala Arg Ser Ala Val Leu Met Leu Leu Leu Leu
1 5  10 15
Phe Ala Leu Asp Asn Phe Val Gly Val Gin Pro Gly Gin l i e  Thr Arg
20 25 30
Asp Val Asp Asn Arg Arg Asn Leu Gin Ser Arg Trp Lys Pro Arg Ser
35 40 45
Leu Phe Lys Ser Leu His Lys Arg Ala Ser Cys Gly Gly Thr Cys Thr
50 55 60
Glu Ser Ala Asp Cys Pro Ser Thr Cys Ser Thr Cys Leu His Ala Gin
65 70 75 80
Cys Glu
<210> SEQ ID NO 25
<2 11> LENGTH: 428
<212> TYPE: DNA
<213> ORGANISM: Conus consors
<220> FEATURE:
<221> NAME/KEY: CDS 
<222> LOCATION: (1) . . (216)
<400> SEQUENCE: 25
a tg  t t g  c t t  c tg  c tg  t t t  gcc t t g  ggc a te  t t c  g t t  ggg gtc cag cca 
Met Leu Leu Leu Leu Phe Ala Leu Gly l i e  Phe Val Gly Val Gin Pro
1 5  10 15
gaa cag a ta  aca aga gat gtg gac aag gga tac  tc c  acg gat gat ggc 
Glu Gin l i e  Thr Arg Asp Val Asp Lys Gly Tyr Ser Thr Asp Asp Gly 
20 25 30
c a t gac c tg  e ta  teg  c tg  t t g  aag caa a te  agt c tc  cgc geg tg t  aca 













ggg t e t  tgc a a t ag t gac age gaa tgc ta c  aa t t t c  tgc gac tgc a t t  192
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Gly Ser Cys Asn Ser Asp Ser Glu Cys Tyr Asn Phe Cys Asp Cys l i e
50 55 60
ggg acc aga t g t  gag gca caa aag tagacgtcag aagaaaaggt cccagtcgct 
Gly Thr Arg Cys Glu Ala Gin Lys 
65 70
caaggcaaga
ttc ta c tg c g
t t t t c g tg tg
gt
actaaacg ta
tg ta ta tc g a
t t c c a t t t c c
gagag tttcc
ccaaacgacg
a tg a c c tt ta
ccg tcaacat
c a t c t t t t a t
ctgcccaaca
gatgtcgcac
t t c t t t g t c t
c tta tc c tg a
tacaacgc ta
g tt tg a g t tg
taaccagaag
<210> SEQ ID NO 26
<2 11> LENGTH: 72
<212> TYPE: PRT
<213> ORGANISM: Conus consors
<400> SEQUENCE: 26
Met Leu Leu Leu Leu Phe Ala Leu Gly l i e  Phe Val Gly Val Gin Pro
1 5  10 15
Glu Gin l i e  Thr Arg Asp Val Asp Lys Gly Tyr Ser Thr Asp Asp Gly
20 25 30
His Asp Leu Leu Ser Leu Leu Lys Gin l i e  Ser Leu Arg Ala Cys Thr
35 40 45
Gly Ser Cys Asn Ser Asp Ser Glu Cys Tyr Asn Phe Cys Asp Cys l i e
50 55 60
Gly Thr Arg Cys Glu Ala Gin Lys 
65 70
<210> SEQ ID NO 27
<2 11> LENGTH: 450
<212> TYPE: DNA
<213> ORGANISM: Conus g lo riam aris
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (27 ) . . (290)
<400> SEQUENCE: 27
cccagaaagg aaacacagcg g tta a a  a tg  c a t c tg  te a  c tg  gca ege te a  get
Met His Leu Ser Leu Ala Arg Ser Ala
1 5
g t t  t t g  a tg  t t g  c t t  c tg  c tg  t t t  gcc t t g  ggc aac t t t  g t t  gtg gtc 
Val Leu Met Leu Leu Leu Leu Phe Ala Leu Gly Asn Phe Val Val Val
10 15 20 25
cag te a  gga c tg  a ta  aca aga gat gtg gac aa t gga cag c tc  acg gac 
Gin Ser Gly Leu l i e  Thr Arg Asp Val Asp Asn Gly Gin Leu Thr Asp
30 35 40
aac ege cg t aac c tg  caa acg gag tgg aac cca t t g  ag t c tc  t t c  atg  
Asn Arg Arg Asn Leu Gin Thr Glu Trp Asn Pro Leu Ser Leu Phe Met
45 50 55
te a  cga egg t e t  t g t  aac aa t t e t  tgc cag age ca t tc c  gat tgc gca 
Ser Arg Arg Ser Cys Asn Asn Ser Cys Gin Ser His Ser Asp Cys Ala
60 65 70
tc c  ca t t g t  a t t  tgc  acg t t t  aga gga tgc gga get gtc a a t ggt 
Ser His Cys l i e  Cys Thr Phe Arg Gly Cys Gly Ala Val Asn Gly
75 80 85













c a t c g a c c a a  a c g a c g c a t c  t t t t a t t t c t  t t g t c t g t t g  t a t t t g t t t t  c c t g t g t t c a  4 1 0
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taacg tacag  ag c c c ttta a  t t a c c t t t a c  tg c tc ttc a c
<210> SEQ ID NO 28
<2 11> LENGTH: 88
<212> TYPE: PRT
<213> ORGANISM: Conus g lo riam aris
<400> SEQUENCE: 28
Met His Leu Ser Leu Ala Arg Ser Ala Val Leu Met Leu Leu Leu Leu
1 5  10 15
Phe Ala Leu Gly Asn Phe Val Val Val Gin Ser Gly Leu l i e  Thr Arg
20 25 30
Asp Val Asp Asn Gly Gin Leu Thr Asp Asn Arg Arg Asn Leu Gin Thr
35 40 45
Glu Trp Asn Pro Leu Ser Leu Phe Met Ser Arg Arg Ser Cys Asn Asn
50 55 60
Ser Cys Gin Ser His Ser Asp Cys Ala Ser His Cys l i e  Cys Thr Phe
65 70 75 80
Arg Gly Cys Gly Ala Val Asn Gly 
85
A O V SEQ ID NO 29
<2 11> LENGTH: 524
<2 12> TYPE: DNA
<2 13> ORGANISM: Conus im p e ria lis
<220> FEATURE:ACNCNV NAME/KEY: CDS
<222> LOCATION: (7) . . (285 )
AOOV SEQUENCE: 29
g ttaaa  a tg  c a t c tg  te a  c tg  gca age te a  get get t t g  atg  t t g  c t t  48
Met His Leu Ser Leu Ala Ser Ser Ala Ala Leu Met Leu Leu
1 5  10
c tg  c t t  t t t  gcc t t g  ggc aac t t c  g t t  ggg gtc cag cca gga caa a ta  96
Leu Leu Phe Ala Leu Gly Asn Phe Val Gly Val Gin Pro Gly Gin l i e  
15 20 25 30
aga gat c tg  aac aaa gga cag c tc  aag gac aac ege cg t aac c tg  caa 
Arg Asp Leu Asn Lys Gly Gin Leu Lys Asp Asn Arg Arg Asn Leu Gin
35 40 45
teg  cag agg aaa caa a tg  ag t c tc  c tc  aag te a  c t t  c a t gat cga aa t 
Ser Gin Arg Lys Gin Met Ser Leu Leu Lys Ser Leu His Asp Arg Asn
50 55 60
ggg tg t  aac ggc aac acg tg t  tc c  a a t age ccc tgc cc t aac aac tg t  
Gly Cys Asn Gly Asn Thr Cys Ser Asn Ser Pro Cys Pro Asn Asn Cys 
65 70 75
t a t  tgc gat a c t gag gac gac tgc cac cc t gac agg cg t gaa ca t 285 
Tyr Cys Asp Thr Glu Asp Asp Cys His Pro Asp Arg Arg Glu His
80 85 90
tag ag a ttag  a g a g tt tc c t tg tcaaca tg  atg tcgcacc acacctc tgc  te tg e a g tg t 345
g tacatcgac cagtcgacgc a t c t g t t a t t  t c t t t g t c t g  t tg g a t tg ta  catcgaccag 405
tccacgcatc  t g t t a t t t c t  t t g t c t g t t t  g a t t t g t t t t  c g tg tg ttc a  taacacacag 465
a g c c t t tc ta  t t a t c t g t a t  tgcaa tacac  t t tg c c tg a t  aaccagaaag tc c a g tg c t 524
< 2 1 0 >  SEQ I D  NO 3 0
<2  1 1> LENGTH:  93
< 2 1 2 >  T Y P E :  PR T
US 2006/0205656 A l
28
Sep. 14, 2006
- c o n t i n u e d




His Leu Ser Leu
5
Ala Ser Ser Ala Ala
10
Leu Met Leu Leu Leu
15
Leu
Phe Ala Leu Gly Asn
20
Phe Val Gly Val
25





Gly Gin Leu Lys Asp
40





Gin Met Ser Leu Leu
55
Lys Ser Leu His Asp
60
Arg Asn Gly Cys
Asn
65
Gly Asn Thr Cys Ser
70
Asn Ser Pro Cys Pro
75
Asn Asn Cys Tyr Cys
80
Asp Thr Glu Asp Asp
85
Cys His Pro Asp Arg
90
Arg Glu His
<210> SEQ ID NO 31 
<2 11> LENGTH: 450 
<212> TYPE: DNA
<213> ORGANISM: Conus pennaceus 
<220> FEATURE:
<221> NAME/KEY: CDS 



















































































































































































taaa cg g a tt g a g tt tg c t t  gtcaacacaa tg tcg cac tg  c a g c tc t tc t  ctaccggtgg 294 
gtacatcgac caaacgacgc a t c t t t t a t t  t c t t t g t c t g  t t t c g t t t g t  tc t c c tg tg t  354 
tc a ta a c g ta  cagagccctt ta a c ta c c c t ta c tg c tc t t  c a c tta a c c t ga taacctga 414
aggtccggtg cagctggcgt agccttcaca  g t t tc g  450
<210> SEQ ID NO 32 
<2 11> LENGTH: 78 
<212> TYPE: PRT
<213> ORGANISM: Conus pennaceus 
<400> SEQUENCE: 32
Met Leu Leu Leu Leu Phe Ala Leu Gly Ser Phe Val Val Val Gin Ser
1 5  10 15
Gly Gin l i e  Thr Arg Asp Val Asp Asn Gly Gin Leu Ala Asp Asn Arg 
20 25 30
Arg Thr Leu Arg Ser Gin Trp Lys Gin Val Ser Phe Phe Lys Ser Leu
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Asp Lys Arg Leu Thr Cys Asn Asp Pro Cys Gin Met His Ser Asp Cys
50 55 60
Gly l i e  Cys Glu Cys Val Glu Asn Lys Cys l i e  Phe Phe Met 
65 70 75
<210> SEQ ID NO 33
<2 11> LENGTH: 811
<212> TYPE: DNA
<213> ORGANISM: Conus t e x t i l e
<220> FEATURE:
<221> NAME/KEY: CDS 
<222> LOCATION: (28 ) . . (294)
<400> SEQUENCE: 33
acccagaaag gaaacacagc gg ttaaa  a tg  c a t c tg  te a  c tg  gca ege te a  get 54
Met His Leu Ser Leu Ala Arg Ser Ala
1 5
g t t  t t g  a tg  t t g  c t t  c tg  c tg  t t t  gcc t t g  ggc aac t t t  g t t  gtg gtc 102
Val Leu Met Leu Leu Leu Leu Phe Ala Leu Gly Asn Phe Val Val Val 
10 15 20 25
cag te a  gga cag a ta  aca aga gat gtg gac aa t gga cag c tc  aca gac 
Gin Ser Gly Gin l i e  Thr Arg Asp Val Asp Asn Gly Gin Leu Thr Asp
30 35 40
aac ege cg t aac c tg  caa teg  aag tgg aag cca gtg ag t c tc  ta c  atg  
Asn Arg Arg Asn Leu Gin Ser Lys Trp Lys Pro Val Ser Leu Tyr Met
45 50 55
te a  cga egg ggt t g t  aac aa t t c t  tgc cag gag ca t tc c  gat tgc gaa 
Ser Arg Arg Gly Cys Asn Asn Ser Cys Gin Glu His Ser Asp Cys Glu
60 65 70
tc c  ca t t g t  a t t  tgc  acg t t t  aga gga tgc gga get g t t  a a t ggt tga 
Ser His Cys l i e  Cys Thr Phe Arg Gly Cys Gly Ala Val Asn Gly 
75 80 85
g tt tg c tc g t caacatgatg tcgcactaca cactacagct c c tc tc ta c a g tg tg ta c a t 354
cgaccaaacg a c g c a tc tt t t a t t t c t t t g tc tg t t g tg t t t g t t t t c c t g tg ttcag aa 414
cgtacagagc c c t t t a a t t a c c tt tg c tg c tc t t c a c t t a acctgataac cagaaggtcc 474
agtgctggcg tag cc ttc ac a g tt te g te a cgtgtagcgc a ttc c c c a c t t tg a t tg g a t 534
a g g g t t t t t t tcc tcaagca g a t t t t g t t t cacgagttcc accagcaaag c t tg tg tc a t 594
c tgcagc tg t a g g ttg g tt t g tc taa tgag aagaaacaaa gctaaacaaa aataaaacac 654
gcaaacaaac tcc tg aac tg a t t t t a a a c t a a t t t tg a tc ta aa g a tcg t aagggaagca 714
agagcaaacc t t t t t t t a t g tg tagcccca caccag tttg c tg g tc t t tg a tta a ttc a g 774
cgagattcag agcacacaca cacacacaca cacaccg 811
<210> SEQ ID NO 34
<2 11> LENGTH: 88
<212> TYPE: PRT
<213> ORGANISM: Conus t e x t i l e
<400> SEQUENCE: 34
Met His Leu Ser Leu Ala Arg Ser Ala Val Leu Met Leu Leu Leu Leu
1 5  10 15
Phe Ala Leu Gly Asn Phe Val Val Val Gin Ser Gly Gin l i e  Thr Arg 
20 25 30
A s p  V a l  A s p  A s n  G l y  G i n  L e u  T h r  A s p  A s n  A r g  A r g  A s n  L e u  G i n  S e r
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35 40 45
Lys Trp Lys Pro Val Ser Leu Tyr Met Ser Arg Arg Gly Cys Asn Asn
50 55  60
Ser Cys Gin Glu His Ser Asp Cys Glu Ser His Cys l i e  Cys Thr Phe
65 70 75 80
Arg Gly Cys Gly Ala Val Asn Gly 
85
What is claimed is:
1. A  substantially pure conopeptide having the sequence
Xaa 1 -Xaa2 -Cy s -Xaa3 -Xaa4-Xaa5 -Xaa6 -Cy s -Xaa7- 
Xaa8 -Xaa9-Xaa 10-Xaa 11 -Cy s -Xaa 12 -Xaa 13 -Xaa 14 - 
Cys-Xaa 15-Xaa 16-Cy s-Xaa 17-Xaa 18-Xaa 19-Xaa20- 
Xaa21-Cys-Xaa22-Xaa23-Xaa24-Xaa25-Xaa26- 
Xaa27-Xaa28
where Xaal may be Ser, Ala, Asn, Leu, Thr, Gly, g-Thr or 
g-Ser; Xaa2 may be des-Xaa2, Ser, Thr, Gly, g-Thr or 
g-Ser; Xaa3 may be Asn, Gin, Gly, Thr, Ser, g-Thr or 
g-Ser; Xaa4 may be des-Xaa4 or Gly; Xaa5 may be 
des-Xaa5, Asn or Asp; Xaa6 may be Ser, Thr, Pro, Hyp 
(hydroxy-Pro), g-Thr or g-Ser; Xaa7 may be Asn, Gin, 
Thr, Ser, g-Thr or g-Ser; Xaa8 may be Glu, Ser, Asn, 
Met, Thr, Gla (y-carboxy-Glu), Nle (norleucine), Asp, 
Gin, g-Thr or g-Ser; Xaa9 may be His, Ser, Asp, Thr, 
g-Thr or g-Ser; Xaa 10 may be Ser, Ala, Pro, Hyp, Thr, 
g-Thr or g-Ser; X aall may be Asp, Glu Gla or any 
synthetic acidic amino acid; Xaal2 maybe des-Xaal2, 
Glu, Asp, Pro, Hyp, Gla, Ala, Tyr, meta-Tyr, ortho-Tyr, 
nor-Tyr, mono-halo-Tyr, ortho-125I-Tyr, di-halo-Tyr, 
O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any syn­
thetic acidic amino acid; Xaa 13 may be Ser, Asn, Gly, 
Thr, Hyp, g-Thr, g-Ser or any synthetic hydroxy con­
taining amino acid; X aal4 maybe His, Thr, Phe, Asn, 
lie, Ser, Gin, g-Ser, g-Thr, any synthetic hydroxy 
containing amino acid, Trp (D or L), neo-Trp, halo-Trp 
(D or L) or any synthetic aromatic amino acid; Xaa 15 
may be lie, Ser, Asp, Glu, Gla, any synthetic amino 
acid, Thr, g-Ser, g-Thr, any synthetic hydroxy contain­
ing amino acid, Tyr, meta-Tyr, ortho-Tyr, nor-Tyr, 
ortho-125I-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho- 
Tyr, O-phospho-Tyr or nitro-Tyr; Xaal6 may be des- 
X aa^ , Thr, Ser, g-Thr, g-Ser or any synthetic hydroxy 
containing amino acid; X aal7 may be des-Xaal7, Asp, 
Glu, Gla or any synthetic acidic amino acid; Xaa 18 
may be Thr, Leu, He, Val, Ser, g-Thr, g-Ser or any 
synthetic hydroxy containing amino acid; Xaa 19 may 
be Phe, His, Gly, Glu, Asp, Gla, any synthetic acidic 
amino acid, Ser, Thr, g-Ser, g-Thr, any synthetic 
hydroxy containing amino acid, Trp (D or L), neo-Trp, 
halo-Trp (D or L) or any synthetic aromatic amino acid; 
Xaa20 may be Ser, Thr, Ala, Asp, Asn, Gin, g-Ser, 
g-Thr, His, Arg, ornithine, homo-Lys, homoaiginine, 
nor-Lys, N-methyl-Lys, N,N'-dimethyl-Lys, N,N',N"- 
trimethyl-Lys or any synthetic basic amino acid; Xaa21 
may be Gly, Gin, Asn, His, Arg, ornithine, homo-Lys, 
homoarginine, nor-Lys, N-methyl-Lys, N,N'-dimethyl- 
Lys, N,N',N"-trimethyl-Lys or any synthetic basic 
amino acid; Xaa22 may be Gly, Glu, Asp, Gla, any
synthetic acidic amino acid, He, His, Aig, ornithine, 
homo-Lys, homoaiginine, nor-Lys, N-methyl-Lys, 
N,N'-dimethyl-Lys, N,N',N"-trimethyl-Lys or any syn­
thetic basic amino acid; X23aa maybe des-Xaa23, He, 
Ala, Ser, Pro, Hyp, Phe, Thr, g-Thr, g-Ser or any 
synthetic hydroxy containing amino acid; Xaa24 may 
be des-Xaa24, He, Val, Thr, Asp, Phe, Ser, g-Thr, g-Ser 
or any synthetic hydroxy containing amino acid; Xaa25 
may be des-Xaa25, Met, Nie, His, Arg, ornithine, 
homo-Lys, homoaiginine, nor-Lys, N-methyl-Lys, 
N,N'-dimethyl-Lys, N,N',N"-trimethyl-Lys or any syn­
thetic basic amino acid; Xaa26 may be des-Xaa26, His, 
Arg, ornithine, homo-Lys, homoarginine, nor-Lys, 
N-methyl-Lys, N,N'-dimethyl-Lys, N,N',N"-trimethyl- 
Lys or any synthetic basic amino acid; Xaa27 may be 
des-Xaa27, Leu, Asn, Gin, Glu, Asp, Gla or any syn­
thetic amino acid; and Xaa28 may be des-Xaa28, He, 
His, Arg, ornithine, homo-Lys, homoarginine, nor-Lys, 
N-methyl-Lys, N,N'-dimethyl-Lys, N,N',N"-trimethyl- 
Lys or any synthetic basic amino acid.
2. The peptide of claim 1, wherein the six Cys residues 
from disulfide bridge pairs, whereby the bridged peptide has 
spasmodic activity.
3. A  derivative o f the peptide of claim 1, in which the Aig 
residues may be substituted by Lys, ornithine, homoaigine, 
nor-Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trim- 
ethyl-Lys or any synthetic basic amino acid; the Lys residues 
may be substituted by Aig, ornithine, homoargine, nor-Lys, 
or any synthetic basic amino acid; the Tyr residues may be 
substituted with meta-Tyr, ortho-Tyr, nor-Tyr, mono-halo- 
Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or 
any synthetic hydroxy containing amino acid; the Ser resi­
dues may be substituted with Thr or any synthetic hydroxy - 
lated amino acid; the Thr residues may be substituted with 
Ser or any synthetic hydroxylated amino acid; the Phe 
residues may be substituted with any synthetic aromatic 
amino acid; the Trp residues maybe substituted with Trp (D), 
neo-Trp, halo-Trp (D or L) (wherby halo is F, Cl, Br, I at the 
indolic positions 5 or 6 or both) or any aromatic synthetic 
amino acid; the Asn, Ser, Thr or Hyp residues may be 
glycosylated;, the Tyr residues may also be substituted with 
the 3-hydroxyl or 2-hydroxyl isomers (meta-Tyr or ortho- 
Tyr, respectively) and corresponding O-sulpho- and O-phos- 
pho-derivatives; the acidic amino acid residues may be 
substituted with any synthetic acidic amino acid, e.g., tet- 
razolyl derivatives o f Gly and Ala; the aliphatic amino acids 
may be substituted by synthetic derivatives bearing non­
natural aliphatic branched or linear side chains CnH2n+2 up 
to and including n=8; the Leu residues may be substituted 
with Leu (D); the Glu residues may be substituted with Gla; 
the Gla residues may be substituted with Glu; the Met
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residues may be substituted by Nle; the Cys residues may be 
in D or L configuration and may optionally be substituted 
with homocysteine (D or L); and pairs o f Cys residues may 
be replaced pairwise with isoteric lactam or ester-thioether 
replacements, such as Ser/Glu (or Asp), Lys/Glu (or Asp), 
Cys/Glu (or Asp), Cys/Ala or Cys/Glu (or Asp) combina­
tions.
4. The substantially pure conopeptide of claim 1 selected 
from the group consisting of:
(SEQ ID NO: 2) 
Ser-Cys-Asn-Asn-Ser-Cys-Asn-Xaal-His-Ser-Asp-Cys- 
X aal-Ser-H is-C ys-Ile-Cys-Thr-Phe-Ser-G ly-C ys-Lys- 
I l e - l ie -L e u - l ie ;
















(SEQ ID NO: 7) 
Ser-Cys-Asn-Asn-Ser-Cys-Gln-Ser-His-Ser-Asp-Cys- 
A la-Ser-His-Cys-Ile-Cys-Thr-Phe-Arg-Gly-Cys-G ly- 
Ala-Val-Asn;




(SEQ ID NO: 9) 
Leu-Thr-Cys-Asn-Asp-Xaa3-Cys-Gln-Met-His-Ser-Asp- 
C ys-G ly-Ile-Cys-Xaal-Cys-V al-Xaal-A sn-Lys-Cys-Ile- 
Phe-Phe-Met;





(SEQ ID NO: 11) 
Gly-Cys-Asn-Asn-Ser-Cys-Gln-Xaal-His-Ser-Asp-Cys- 
X aal-Ser-H is-Cys-Ile-Cys-Thr-Ser-A rg-G ly-Cys-G ly- 
Ala-Val-Asn,
wherein Xaal is Glu or y-carboxy-Glu; Xaa3 is Pro or 
hydroxy-Pro; Xaa5 is Tyr, 1251-Tyr, mono-iodo-Tyr, 
di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr; and the 
C-terminus contains an amide group or a carboxyl 
group.
5. The peptide o f claim 4, wherein the six Cys residues 
from disulfide bridge pairs, whereby the bridged peptide has 
spasmodic activity.
6. A  derivative o f the peptide o f claim 4, in which the Arg 
residues may be substituted by Lys, ornithine, homoargine, 
nor-Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trim- 
ethyl-Lys or any synthetic basic amino acid; the Lys residues
may be substituted by Arg, ornithine, homoaigine, nor-Lys, 
or any synthetic basic amino acid; the Tyr residues may be 
substituted with meta-Tyr, ortho-Tyr, nor-Tyr, mono-halo- 
Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or 
any synthetic hydroxy containing amino acid; the Ser resi­
dues may be substituted with Thr or any synthetic hydroxy - 
lated amino acid; the Thr residues may be substituted with 
Ser or any synthetic hydroxylated amino acid; the Phe 
residues may be substituted with any synthetic aromatic 
amino acid; the Trp residues may be substituted with Trp 
(D), neo-Trp, halo-Trp (D or L) or any aromatic synthetic 
amino acid; the Asn, Ser, Thr or Hyp residues may be 
glycosylated; the Tyr residues may also be substituted with 
the 3-hydroxyl or 2-hydroxyl isomers (meta-Tyr or ortho- 
Tyr, respectively) and corresponding O-sulpho- and O-phos- 
pho-derivatives; the acidic amino acid residues may be 
substituted with any synthetic acidic amino acid, e.g., tet- 
razolyl derivatives o f Gly and Ala; the aliphatic amino acids 
may be substituted by synthetic derivatives bearing non­
natural aliphatic branched or linear side chains CnH2ll+2 up 
to and including n=8; the Leu residues may be substituted 
with Leu (D); the Glu residues may be substituted by Gla; 
the Gla residues may be substituted by Glu; the Met residues 
may be substituted by Nle; the Cys residues may be in D or 
L configuration and may optionally be substituted with 
homocysteine (D or L); and
pairs of Cys residues may be replaced pairwise with 
isoteric lactam or ester-thioether replacements, such as 
Ser/(Glu or Asp), Lys/(Glu or Asp), Cys/(Glu or Asp), 
Cys/Glu (or Asp) or Cys/Ala combinations.
7. A  substantially pure P-Superfamily conopeptide deriva­
tive comprising a permutant of the peptide o f claim 1.
8. A  substantially pure P-Superfamily conopeptide deriva­
tive comprising a permutant of the peptide o f claim 3.
9. A  substantially pure P-Superfamily conopeptide deriva­
tive comprising a permutant of the peptide o f claim 4.
10. A  substantially pure P-Superfamily conopeptide 
derivative comprising a permutant o f the peptide of claim 6.
11. An isolated nucleic acid encoding a P-superfamily 
conopeptide precursor having an amino acid sequence 
selected from the groups consisting of the amino acid 
sequences set forth in SEQ ID NOs:18, 20, 22, 24, 26, 28, 
30, 32 and 34.
12. The isolated nucleic acid o f claim 11, wherein the 
nucleic acid comprises a nucleotide sequence selected from 
the group consisting o f the nucleotide sequences set forth in 
SEQ ID NOs:17, 19,21,23,25, 27,29, 31 and 33.
13. An isolated P-superfamily conopeptide precursor hav­
ing an amino acid sequence selected from the group con­
sisting o f the amino acid sequences set forth in SEQ ID NOs:
18, 20,22, 24, 26, 28, 30, 32 and 34.
14. A  method for screening a drug candidate for anti­
convulsant activity which comprises (a) administering a 
P-Superfamily conopeptide o f claim 1 and said drug candi­
date to a mouse and (b) monitoring the response of said 
mouse, wherein if  the drug candidate prevents a spastic or 
spasmotic response in said mouse, then the drug has anti­
convulsant activity.
15. A  method for treating convulsions which comprises 
administering to a patient in need thereof a therapeutically 
effective amount of a drug identified by the method of claim 
14.
16. A  method for screening a drug candidate for anti­
convulsant activity which comprises (a) administering a
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P-Superfamily conopeptide o f claim 4 and said drug candi­
date to a mouse and (b) monitoring the response o f said 
mouse, wherein if  the drug candidate prevents a spastic or 
spasmotic response in said mouse, then the drug has anti­
convulsant activity.
17. A  method for treating convulsions which comprises 
administering to a patient in need thereof a therapeutically 
effective amount o f a drug identified by the method o f claim 
26.
18. A  method o f identifying compounds that mimic the 
therapeutic activity o f a P-Superfamily conopeptide, com­
prising the steps of: (a) conducting a biological assay on a 
test compound to determine the therapeutic activity; and (b) 
comparing the results obtained from the biological assay of  
the test compound to the results obtained from the biological 
assay of a P-Superfamily conopeptide o f claim 1.
19. A  method o f identifying compounds that mimic the 
therapeutic activity o f a P-Superfamily conopeptide, com­
prising the steps of: (a) conducting a biological assay on a
test compound to determine the therapeutic activity; and (b) 
comparing the results obtained from the biological assay o f 
the test compound to the results obtained from the biological 
assay o f a P-Superfamily conopeptide o f claim 4.
20. A  method for making a pharmaceutical formulation 
for the treatment o f convulsions which comprises:
(a) co-administering candidate compounds and a P-Su- 
perfamily conopeptide o f claim 1 to a mouse;
(b) selecting a compound identified in step (a) which 
prevents a spastic or spasmotic response in said mouse;
(c) manufacturing bulk quantities o f the compound 
selected in step (b); and
(d) formulating the compound manufactured in step (c) in 
a pharmaceutically acceptable carrier.
